[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4254
1. Öztürk A, Akyol Erikci A, Sayan Ö: Results of treatment of acute myeloid leukemia and myelodysplastic syndrome with etoposide, thioguanine, cytarabine (ETC) in elderly patients. Turk J Haematol; 2006 Dec 5;23(4):193-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment of acute myeloid leukemia and myelodysplastic syndrome with etoposide, thioguanine, cytarabine (ETC) in elderly patients.
  • [Transliterated title] Yaşlı akut myeloid lösemili ve myelodisplastik sendromlu hastalarda etoposid, thioguanin, sitarabin tedavisinin sonuçları.
  • Treatment in elderly patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains controversial, and results have been poor with most regimens.
  • In order to study the efficacy of a new regimen in the treatment of these diseases in elderly patients assessed as not tolerating full-scale anthracycline-containing intensive chemotherapy, 14 patients over 60 years were enrolled in our study.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265661.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


2. Fortier JM, Payton JE, Cahan P, Ley TJ, Walter MJ, Graubert TA: POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature. Leukemia; 2010 May;24(5):950-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature.
  • The t(8;21)(q22;q22) translocation, present in approximately 5% of adult acute myeloid leukemia (AML) cases, produces the AML1/ETO (AE) fusion protein.
  • Dysregulation of the Pit/Oct/Unc (POU) domain-containing transcription factor POU4F1 is a recurring abnormality in t(8;21) AML.
  • We observed that AE markedly increases the self-renewal capacity of myeloid progenitors from murine bone marrow or fetal liver and drives the expansion of these cells in liquid culture.
  • POU4F1 is neither necessary nor sufficient for these AE-dependent properties, suggesting that it contributes to leukemia through novel mechanisms.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Death Differ. 2008 Aug;15(8):1266-78 [18421303.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):7165-75 [18757432.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7819-27 [18829537.001]
  • [Cites] Nature. 1989 Jul 6;340(6228):35-41 [2739723.001]
  • [Cites] Blood. 1993 Aug 1;82(3):712-5 [8338940.001]
  • [Cites] Nucleic Acids Res. 1993 Dec 25;21(25):5921-9 [8290353.001]
  • [Cites] Mol Cell Biol. 1995 Apr;15(4):1974-82 [7891692.001]
  • [Cites] Oncogene. 2002 May 23;21(23):3814-25 [12032850.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):63-74 [12086889.001]
  • [Cites] Mol Cell Biol. 2002 Aug;22(15):5506-17 [12101243.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10008-13 [12105272.001]
  • [Cites] Oncogene. 2002 Sep 5;21(39):6123-31 [12203124.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Exp Hematol. 2003 Feb;31(2):159-67 [12591281.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jun;37(2):149-58 [12696063.001]
  • [Cites] Development. 2003 Aug;130(15):3525-34 [12810599.001]
  • [Cites] Nat Genet. 2003 Jul;34(3):267-73 [12808457.001]
  • [Cites] Cancer Cell. 2003 Jul;4(1):19-29 [12892710.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9506-11 [12881486.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1605-16 [15084693.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6062-7 [15075390.001]
  • [Cites] Leuk Res. 2004 Sep;28(9):973-7 [15234575.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15184-9 [15477599.001]
  • [Cites] Cancer. 2004 Nov 1;101(9):2006-10 [15386301.001]
  • [Cites] PLoS Genet. 2008 Nov;4(11):e1000275 [19043539.001]
  • [Cites] Nat Protoc. 2009;4(1):44-57 [19131956.001]
  • [Cites] BMC Genomics. 2009;10:22 [19144180.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3788-93 [19234109.001]
  • [Cites] Nature. 1996 Apr 25;380(6576):711-4 [8614465.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11950-5 [8876243.001]
  • [Cites] Nature. 1996 Dec 12;384(6609):574-7 [8955272.001]
  • [Cites] Eur J Immunol. 1997 May;27(5):1292-5 [9174623.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10860-5 [9724795.001]
  • [Cites] Cell. 1998 Oct 30;95(3):379-91 [9814708.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):104-12 [10077160.001]
  • [Cites] J Mol Endocrinol. 1999 Jun;22(3):295-304 [10343288.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jun 24;260(1):216-21 [10381369.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3679-87 [15226186.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4016-21 [15731354.001]
  • [Cites] Cell. 2005 May 6;121(3):465-77 [15882627.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] J Neurosci. 2005 Dec 14;25(50):11595-604 [16354917.001]
  • [Cites] Blood. 2006 Jan 15;107(2):733-41 [16204320.001]
  • [Cites] Br J Haematol. 2006 Nov;135(3):336-47 [16989659.001]
  • [Cites] Mol Endocrinol. 2006 Dec;20(12):3400-11 [16931572.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1291-300 [17485551.001]
  • [Cites] Leukemia. 2007 Dec;21(12):2495-505 [17898786.001]
  • [Cites] Development. 2008 Jan;135(2):401-10 [18156164.001]
  • [Cites] Blood. 2008 May 1;111(9):4797-808 [18270328.001]
  • [Cites] Nat Genet. 2000 Apr;24(4):372-6 [10742100.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7521-6 [10861016.001]
  • [Cites] Brain Res Mol Brain Res. 2000 Jun 23;79(1-2):180-91 [10925158.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10398-403 [11526243.001]
  • [Cites] Cell. 2001 Oct 19;107(2):209-21 [11672528.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3070-5 [11867721.001]
  • [Cites] Leukemia. 2002 May;16(5):874-85 [11986950.001]
  • (PMID = 20376082.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA101937; United States / NCI NIH HHS / CA / P01 CA101937-010006; United States / NCI NIH HHS / CA / P30 CA091842; United States / NCI NIH HHS / CA / P30 CA91842
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Biomarkers, Tumor; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / POU4F1 protein, human; 0 / Pou4f1 protein, mouse; 0 / RNA, Messenger; 0 / Transcription Factor Brn-3A
  • [Other-IDs] NLM/ NIHMS183891; NLM/ PMC2868953
  •  go-up   go-down


3. Sumi M, Tauchi T, Takaku T, Ohyashiki JH, Ohyashiki K: [Successful treatment with interferon-alpha in a case of acute myeloid leukemia with del (20q) following polycythemia vera]. Rinsho Ketsueki; 2005 Nov;46(11):1208-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment with interferon-alpha in a case of acute myeloid leukemia with del (20q) following polycythemia vera].
  • Polycythemia vera (PV) is a hematopoietic stem cell clonal disorder, 5 to approximately 10% of which will evolve into acute leukemia.
  • The pathophysiology of leukemic transformation and the best therapy for the leukemic phase of PV is still unknown.
  • A 73-year-old woman was given a diagnosis of PV 17 years previously.
  • The leukemic phase of PV was diagnosed.
  • As far as we know, this is the first report of the introduction of IFN-alpha in the treatement of the leukemic phase of PV.
  • Further monitoring of this patient will provide valuable information concerning the pathophysiology of leukemic transformation and the development of effective therapy for the leukemic phase of PV.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Chromosomes, Human, Pair 20 / genetics. Interferon-alpha / therapeutic use. Leukemia, Myeloid, Acute / etiology. Polycythemia Vera / complications
  • [MeSH-minor] Cell Transformation, Neoplastic. Chromosome Deletion. Disease Progression. Female. Humans. Middle Aged. Treatment Outcome


Advertisement
4. Leinoe EB, Hoffmann MH, Kjaersgaard E, Nielsen JD, Bergmann OJ, Klausen TW, Johnsen HE: Prediction of haemorrhage in the early stage of acute myeloid leukaemia by flow cytometric analysis of platelet function. Br J Haematol; 2005 Feb;128(4):526-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of haemorrhage in the early stage of acute myeloid leukaemia by flow cytometric analysis of platelet function.
  • Haemorrhage is often responsible for the lethal course of acute myeloid leukaemia (AML).
  • The objective of this prospective study was to analyse platelet function in 50 AML patients at diagnosis and to compare results with clinical bleeding score, graded by common toxicity criteria.
  • In a multivariate analysis, P-selectin (CD62P) <36 molecules of equivalent soluble fluorochrome x 10(3) (P < 0.0015) and platelet count <40 x 10(9)/l (P = 0.01) were significant predictors of haemorrhage at diagnosis.
  • Haemorrhage at diagnosis predicted grade 3-4 haemorrhage in the first 28 d following diagnosis (P = 0.018).
  • [MeSH-major] Hemorrhage / etiology. Leukemia, Myeloid / complications
  • [MeSH-minor] Acute Disease. Aged. Biomarkers / blood. Blood Specimen Collection / methods. Flow Cytometry / methods. Hemostasis. Humans. Middle Aged. P-Selectin / blood. Platelet Activation. Platelet Count. Platelet Function Tests / methods. Prognosis. Prospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Bleeding.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15686463.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / P-Selectin
  •  go-up   go-down


5. Wang YX, Zhang JH, Gu ZW: [Beta-catenin and cyclin D1 mRNA levels in newly diagnosed patients with acute myeloid leukemia and their significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr;17(2):304-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Beta-catenin and cyclin D1 mRNA levels in newly diagnosed patients with acute myeloid leukemia and their significance].
  • This study was aimed to quantitatively detect the levels of beta-catenin and cyclin D1 mRNA in various subgroups of acute myeloid leukemia (AML) and to analyze their potential relationship, so as to provide theoretical basis for exploring the role of Wnt/beta-catenin pathway in the pathogenesis of AML.
  • The results showed that the beta-catenin mRNA expression level in BMMNC of AML patients was significantly higher than that in benign blood disease patients (p < 0.05), but no statistical difference was found among the various subgroups of AML (p > 0.05).
  • In AML there was overexpression of cyclin D1 mRNA, and its expression level was significantly higher than that in benign blood disease group (p < 0.05), but there was no statistical difference among the subtypes of AML.
  • It is concluded that the over-expressions of beta-catenin and cyclin D1 exit in AML patients, and the significant correlation appears in part of the subgroups, which means that the Wnt/beta-catenin pathway is aberrantly activated in AML, probably activating the downstream target gene cyclin D1 and participating in the regulation of cell cycle disturbance and abnormal proliferation of leukemic cells.


6. Fröhling S, Schlenk RF, Krauter J, Thiede C, Ehninger G, Haase D, Harder L, Kreitmeier S, Scholl C, Caligiuri MA, Bloomfield CD, Döhner H, Döhner K: Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations. Genes Chromosomes Cancer; 2005 Apr;42(4):427-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations.
  • To assess the prevalence of mutations in the CEBPA gene, which encodes the myeloid transcription factor CEBPA in specific cytogenetic subgroups, we initially studied 125 patients with acute myeloid leukemia (AML).
  • Five of the eight patients with del(9q) as the sole aberration or in combination with a single additional abnormality other than t(8;21) had CEBPA mutations associated with loss of CEBPA function.
  • We have shown for the first time that AML with del(9q) in the context of a noncomplex karyotype is strongly associated with CEBPA loss-of-function mutations.
  • Loss of a critical segment of 9q, most likely in 9q22, and disruption of CEBPA function possibly cooperate in the pathogenesis of del(9q) AML.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 9. Leukemia, Myeloid / genetics. Mutation. Transcription Factors / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Base Sequence. Cohort Studies. DNA Primers. Humans. Middle Aged

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15645492.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 10114 0; United States / NCI NIH HHS / CA / CA 16058; United States / NCI NIH HHS / CA / CA 77658
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Transcription Factors
  •  go-up   go-down


7. Veach DR, Namavari M, Beresten T, Balatoni J, Minchenko M, Djaballah H, Finn RD, Clarkson B, Gelovani JG, Bornmann WG, Larson SM: Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors. Nucl Med Biol; 2005 May;32(4):313-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pyridopyrimidinones are a potent class of inhibitors of c-Abl kinase and Bcr-Abl kinase, the causative fusion protein in chronic myelogenous leukemia and Src family kinases.
  • The radioiodination of 4'-stannylpyridopyrimidinones was found to optimally occur via an iododestannylation with Na(124)I, Na(125)I or Na(131)I in the presence of an oxidant [30% H(2)O(2)/HOAc (1:3)/10 min] in 79-87% radiochemical yield with >99% radiochemical purity.

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15878500.001).
  • [ISSN] 0969-8051
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA064593; United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / P50 CA86438
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(4-iodophenylamino)pyrido(2,3-d)pyrimidin-7-one; 0 / Iodine Radioisotopes; 0 / PD 173074; 0 / Pyridones; 0 / Pyrimidines; 0 / Radiopharmaceuticals; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


8. Brennan P, Scélo G, Hemminki K, Mellemkjaer L, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride ML, Kliewer EV, Tonita JM, Seow A, Pompe-Kirn V, Martos C, Jonasson JG, Colin D, Boffetta P: Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. Br J Cancer; 2005 Jul 11;93(1):159-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma.
  • An analysis of other primary cancers in individuals with non-Hodgkin's lymphoma (NHL) can help to elucidate this cancer aetiology.
  • There was a 47% (95% confidence interval 43-51%) overall increase in the risk of a primary cancer after NHL.
  • A strongly significant (P<0.001) increase was observed for cancers of the lip, tongue, oropharynx*, stomach, small intestine, colon*, liver, nasal cavity*, lung, soft tissues*, skin melanoma*, nonmelanoma skin*, bladder*, kidney*, thyroid*, Hodgkin's lymphoma*, lymphoid leukaemia* and myeloid leukaemia.
  • Non-Hodgkin's lymphoma as a second primary was increased after cancers marked with an asterisk.
  • Patterns of risk indicate a treatment effect for lung, bladder, stomach, Hodgkin's lymphoma and myeloid leukaemia.
  • Bidirectional effects for several cancer sites of potential viral origin argue strongly for a role for immune suppression in NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):1-8 [15185336.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):431-7 [15006920.001]
  • [Cites] Natl Cancer Inst Monogr. 1985 Dec;68:3-9 [4088304.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440 [3482203.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):2002-9 [2004317.001]
  • [Cites] Cancer. 1992 May 1;69(9):2337-42 [1562981.001]
  • [Cites] Leuk Lymphoma. 1994 Aug;14(5-6):387-94 [7812197.001]
  • [Cites] BMJ. 1995 Jun 10;310(6993):1491-5 [7787593.001]
  • [Cites] Br J Cancer. 1996 Apr;73(7):945-50 [8611412.001]
  • [Cites] Am J Epidemiol. 1997 Jun 15;145(12):1061-75 [9199536.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):923-30 [9378552.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jan;7(1):25-8 [9456239.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1995;64:1-378 [16755705.001]
  • [Cites] Leuk Lymphoma. 2000 Apr;37(3-4):341-9 [10752985.001]
  • [Cites] Br J Cancer. 2000 Apr;82(7):1344-7 [10755412.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2000;75 Pt 1:35-115 [10932818.001]
  • [Cites] Int J Cancer. 2001 Jul 15;93(2):288-93 [11410879.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):997-1005 [11592772.001]
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):813-20 [11714109.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(2):223-9 [12509955.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):74-8 [12556962.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2087-92 [14647142.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):865-71 [15386383.001]
  • (PMID = 15970927.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA101442; United States / NCI NIH HHS / CA / R03 CA101442-02
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361473
  •  go-up   go-down


9. Pagano L, Caira M, Valentini CG, Posteraro B, Fianchi L: Current therapeutic approaches to fungal infections in immunocompromised hematological patients. Blood Rev; 2010 Mar;24(2):51-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with acute myeloid leukemia and those who have undergone allogeneic hematopoietic stem cell transplantation are at especially high risk.
  • [MeSH-major] Antifungal Agents / therapeutic use. Hematologic Diseases / complications. Immunocompromised Host. Mycoses / drug therapy

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20056300.001).
  • [ISSN] 1532-1681
  • [Journal-full-title] Blood reviews
  • [ISO-abbreviation] Blood Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents
  • [Number-of-references] 128
  •  go-up   go-down


10. Naoghare PK, Kim MJ, Song JM: Uniform threshold intensity distribution-based quantitative multivariate imaging cytometry. Anal Chem; 2008 Jul 15;80(14):5407-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An acousto-optic tunable filter-based, quantitative multivariate imaging cytometer was set up to elucidate drug-induced cell death dynamics via cell viability and apoptosis/necrosis measurements in the human myeloid leukemia cell line, HL-60.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18512945.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Trnková Z, Bedrlíková R, Marková J, Michalová K, Stöckbauer P, Schwarz J: Semiquantitative RT-PCR evaluation of the MDR1 gene expression in patients with acute myeloid leukemia. Neoplasma; 2007;54(5):383-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Semiquantitative RT-PCR evaluation of the MDR1 gene expression in patients with acute myeloid leukemia.
  • Resistance to chemotherapy is one of the major obstacles to effective treatment in acute myeloid leukemia (AML).
  • MDR1/P-gp overexpression is frequently observed in hematological malignancies, especially in acute leukemia, and has been reported to correlate with poor prognosis in acute myeloid leukemia (AML).
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Leukemia, Myeloid / genetics. P-Glycoprotein / genetics
  • [MeSH-minor] Acute Disease. DNA Primers. Gene Amplification. Humans. Proto-Oncogene Proteins c-bcr / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17688368.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / DNA Primers; 0 / P-Glycoprotein; EC 2.7.11.1 / Proto-Oncogene Proteins c-bcr
  •  go-up   go-down


12. Liang DC, Shih LY, Fu JF, Li HY, Wang HI, Hung IJ, Yang CP, Jaing TH, Chen SH, Liu HC: K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. Cancer; 2006 Feb 15;106(4):950-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements.
  • BACKGROUND: It is believed that Ras mutations drive the proliferation of leukemic cells.
  • The objective of this study was to investigate the association of Ras mutations with childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) with special reference to the presence or absence of mixed-lineage leukemia gene (MLL) rearrangements.
  • METHODS: Bone marrow samples from 313 children with B-precursor ALL and 130 children with de novo AML were studied at diagnosis.
  • RESULTS: Twenty of 313 patients with B-precursor ALL and 17 of 130 patients with de novo AML had MLL rearrangements.
  • [MeSH-major] Gene Rearrangement. Genes, ras. Leukemia, Myeloid / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Blotting, Southern. Child. Child, Preschool. DNA Mutational Analysis. Female. Humans. Infant. Male. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16404744.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Morrison AA, Ladomery MR: Presence of WT1 in nuclear messenger RNP particles in the human acute myeloid leukemia cell lines HL60 and K562. Cancer Lett; 2006 Nov 28;244(1):136-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of WT1 in nuclear messenger RNP particles in the human acute myeloid leukemia cell lines HL60 and K562.
  • The WT1 gene is a key player in acute myeloid leukaemia, in which it is frequently over-expressed.
  • Nuclear poly(A)(+) mRNP particles were isolated by oligo(dT) chromatography from the human acute myeloid leukemia cell lines HL60 and K562, and analysed by Western blotting and 2D minigels.
  • WT1 was also shown to be present in nuclear mRNP particles suggesting that in leukaemia, and by extension in all cancers in which it is involved, WT1 works both at the DNA and mRNA target level.
  • [MeSH-major] Cell Nucleus / metabolism. DNA / metabolism. Leukemia, Myeloid / metabolism. RNA, Messenger / metabolism. Ribonucleoproteins / metabolism. WT1 Proteins / metabolism
  • [MeSH-minor] Acute Disease. Electrophoresis, Gel, Two-Dimensional. HL-60 Cells. Humans. K562 Cells. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16457949.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Ribonucleoproteins; 0 / WT1 Proteins; 0 / messenger ribonucleoprotein; 9007-49-2 / DNA
  •  go-up   go-down


14. Firat F, Ozen G, Yildiz G, Sağlam A, Onder S, Tan E, Ozdemir E: Late relapse of acute myeloblastic leukemia as myeloid sarcoma causing radiculopathy. Leuk Res; 2010 Dec;34(12):e348-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late relapse of acute myeloblastic leukemia as myeloid sarcoma causing radiculopathy.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Neoplasms, Second Primary / pathology. Radiculopathy / pathology. Sarcoma, Myeloid / pathology


15. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, Haferlach T, Hiddemann W, Falini B: Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood; 2005 Dec 1;106(12):3733-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.
  • Nucleophosmin (NPM1) exon-12 gene mutations are the hallmark of a large acute myelogenous leukemia (AML) subgroup with normal karyotype, but their prognostic value in this AML subset has not yet been determined.
  • This positive effect was lost in the presence of a concomitant FLT3-LM, since survival of the NPM1+/FLT3-LM+ double positive was similar to NPM1-/FLT3-LM+ cases.
  • In conclusion, this study demonstrates that NPM1+/FLT3-LM- mutations are an independent predictor for a favorable outcome in AML with normal karyotype.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. DNA Mutational Analysis. Disease-Free Survival. Female. Humans. Male. Middle Aged. Mutation. Prognosis. Survival Analysis


16. Wertheim G, Bagg A: Nucleophosmin (NPM1) mutations in acute myeloid leukemia: an ongoing (cytoplasmic) tale of dueling mutations and duality of molecular genetic testing methodologies. J Mol Diagn; 2008 May;10(3):198-202
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleophosmin (NPM1) mutations in acute myeloid leukemia: an ongoing (cytoplasmic) tale of dueling mutations and duality of molecular genetic testing methodologies.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / genetics. Molecular Biology. Molecular Diagnostic Techniques. Mutation. Nuclear Proteins / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Diagn. 2003 Nov;5(4):231-6 [14573782.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Br J Haematol. 1999 Oct;107(1):69-79 [10520026.001]
  • [Cites] N Engl J Med. 2005 Jan 20;352(3):254-66 [15659725.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1479-82 [15973451.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1153-60 [15889156.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3740-6 [16051734.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):254-9 [16645213.001]
  • [Cites] Blood. 2006 May 15;107(10):4011-20 [16455956.001]
  • [Cites] Leukemia. 2006 Jun;20(6):1103-8 [16541144.001]
  • [Cites] Blood. 2006 Jul 1;108(1):28-37 [16522812.001]
  • [Cites] Blood. 2006 Sep 15;108(6):1999-2005 [16720834.001]
  • [Cites] Haematologica. 2006 Sep;91(9):1283-4 [16956837.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1897-9 [17041639.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:169-77 [17124057.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:178-84 [17124058.001]
  • [Cites] Lancet. 2006 Nov 25;368(9550):1894-907 [17126723.001]
  • [Cites] Blood. 2007 Feb 1;109(3):874-85 [17008539.001]
  • [Cites] Leukemia. 2007 May;21(5):998-1004 [17361227.001]
  • [Cites] Leuk Res. 2007 Sep;31(9):1205-11 [17306368.001]
  • [Cites] Haematologica. 2007 Sep;92(9):1268-9 [17768124.001]
  • [Cites] Oncogene. 2007 Nov 22;26(53):7391-400 [17546053.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2776-84 [17957027.001]
  • [Cites] J Mol Diagn. 2008 May;10(3):236-41 [18403605.001]
  • [Cites] J Mol Diagn. 2008 May;10(3):212-6 [18403613.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Curr Opin Oncol. 2002 Jan;14(1):10-8 [11790974.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:179-98 [12194988.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • (PMID = 18403611.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin
  • [Other-IDs] NLM/ PMC2329783
  •  go-up   go-down


17. Smith KA, Griffin JD: Following the cytokine signaling pathway to leukemogenesis: a chronology. J Clin Invest; 2008 Nov;118(11):3564-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During that same period, the molecular and genetic changes introduced by the Philadelphia chromosome in chronic myelogenous leukemia were unraveled, and these have led to an understanding of how mutations that constitutively activate normal cytokine signaling pathways can cause unregulated cell proliferation and malignant transformation.
  • [MeSH-major] Cell Physiological Phenomena. Cytokines / physiology. Leukemia / etiology. Leukemia / pathology. Signal Transduction / physiology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1991 Apr 11;350(6318):512-5 [1826542.001]
  • [Cites] Cell. 1991 May 17;65(4):701-13 [1827757.001]
  • [Cites] Mol Cell Biol. 1991 Oct;11(10):4846-53 [1833629.001]
  • [Cites] Cell. 1992 Jul 24;70(2):313-22 [1386289.001]
  • [Cites] Science. 1992 Aug 7;257(5071):809-13 [1496401.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7836-9 [1502203.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7840-3 [1502204.001]
  • [Cites] Oncogene. 1992 Dec;7(12):2381-7 [1461646.001]
  • [Cites] Cell. 1993 Jul 30;74(2):227-36 [8343951.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8429-33 [8378315.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3524-9 [7505115.001]
  • [Cites] Int Immunol. 1993 Oct;5(10):1199-209 [8268127.001]
  • [Cites] Science. 1994 Apr 1;264(5155):95-8 [8140422.001]
  • [Cites] EMBO J. 1994 May 1;13(9):2182-91 [7514531.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 24;91(11):4806-10 [7545930.001]
  • [Cites] Science. 1994 Jun 3;264(5164):1415-21 [8197455.001]
  • [Cites] Nature. 1994 Jul 14;370(6485):151-3 [8022485.001]
  • [Cites] Nature. 1994 Jul 14;370(6485):153-7 [8022486.001]
  • [Cites] Science. 1994 Sep 16;265(5179):1701-6 [8085155.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Sep 15;203(2):922-8 [7522448.001]
  • [Cites] EMBO J. 1994 Dec 1;13(23):5605-15 [7988557.001]
  • [Cites] Science. 1995 Mar 24;267(5205):1782-8 [7892601.001]
  • [Cites] Immunity. 1995 Apr;2(4):321-9 [7719937.001]
  • [Cites] EMBO J. 1995 Mar 15;14(6):1166-75 [7720707.001]
  • [Cites] Science. 1995 Jul 7;269(5220):81-3 [7541555.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8831-5 [7568026.001]
  • [Cites] Science. 1995 Sep 29;269(5232):1875-7 [7569929.001]
  • [Cites] Ann N Y Acad Sci. 1995 Sep 7;766:263-71 [7486669.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] J Biol Chem. 1996 May 3;271(18):10738-44 [8631883.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2535-40 [9326218.001]
  • [Cites] Science. 1997 Nov 14;278(5341):1309-12 [9360930.001]
  • [Cites] J Cell Physiol. 1997 Nov;173(2):233-6 [9365528.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2545-52 [9566874.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2553-8 [9566875.001]
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • [Cites] Proc Soc Exp Biol Med. 1951 Jan;76(1):27-32 [14816382.001]
  • [Cites] J Cell Biol. 1963 May;17:299-313 [13985244.001]
  • [Cites] Science. 1963 Nov 29;142(3596):1185-7 [14069243.001]
  • [Cites] Science. 1964 Feb 21;143(3608):813-4 [14088078.001]
  • [Cites] Science. 1964 Sep 18;145(3638):1315-6 [14173419.001]
  • [Cites] J Natl Cancer Inst. 1960 Apr;24:933-51 [14423465.001]
  • [Cites] J Natl Cancer Inst. 1960 Jul;25:85-109 [14427847.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Apr;75(4):2021-4 [205879.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2076-83 [10706877.001]
  • [Cites] J Exp Med. 2000 Mar 20;191(6):977-84 [10727459.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2269-76 [10979976.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2277-83 [10979977.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6188-95 [11593427.001]
  • [Cites] Annu Rev Cell Biol. 1989;5:397-425 [2688708.001]
  • [Cites] Mol Cell Biol. 1989 Nov;9(11):4605-12 [2513475.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):6934-8 [2169613.001]
  • [Cites] Oncogene. 1990 Sep;5(9):1329-36 [2216457.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8555-9 [2236065.001]
  • [Cites] Mol Cell Biol. 1991 Apr;11(4):2057-65 [1848670.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):18962-7 [16365288.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4898-906 [16493008.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9339-44 [16990346.001]
  • [Cites] Blood. 2008 Jan 1;111(1):344-50 [17890450.001]
  • [Cites] Cancer Res. 1960 May;20:462-6 [14427849.001]
  • [Cites] J Clin Invest. 2002 May;109(9):1139-42 [11994401.001]
  • [Cites] EMBO J. 2002 Nov 1;21(21):5766-74 [12411494.001]
  • [Cites] Blood. 2003 Apr 15;101(8):2940-54 [12480704.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11630-5 [14500898.001]
  • [Cites] J Cell Physiol. 1965 Dec;66(3):325-33 [5884360.001]
  • [Cites] Nature. 1965 Nov 20;208(5012):794-5 [5868897.001]
  • [Cites] Nature. 1965 Nov 20;208(5012):795-6 [4223737.001]
  • [Cites] Science. 1969 Nov 21;166(3908):1019-21 [4981495.001]
  • [Cites] Nature. 1970 Jun 27;226(5252):1209-11 [4316300.001]
  • [Cites] Nature. 1970 Jun 27;226(5252):1211-3 [4316301.001]
  • [Cites] Cancer Res. 1970 Aug;30(8):2213-22 [4318922.001]
  • [Cites] J Natl Cancer Inst. 1971 Feb;46(2):3-7 [5115908.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Oct;68(10):2336-40 [4332808.001]
  • [Cites] J Exp Med. 1972 Jul 1;136(1):128-42 [5033417.001]
  • [Cites] Nature. 1973 Jun 1;243(5405):290-3 [4126434.001]
  • [Cites] Nature. 1974 Apr 19;248(5450):703-4 [4833274.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Apr;71(4):1286-90 [4524638.001]
  • [Cites] Nature. 1976 Mar 11;260(5547):170-3 [176594.001]
  • [Cites] Science. 1976 Sep 10;193(4257):1007-8 [181845.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] Proc Natl Acad Sci U S A. 1977 Oct;74(10):4481-5 [270695.001]
  • [Cites] Nature. 1977 Jul 14;268(5616):154-6 [145543.001]
  • [Cites] J Immunol. 1978 Jun;120(6):2027-32 [307029.001]
  • [Cites] J Exp Med. 1979 Jan 1;149(1):273-8 [310861.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Nov;76(11):5714-8 [230490.001]
  • [Cites] Nature. 1980 Apr 3;284(5755):418-21 [7360280.001]
  • [Cites] J Exp Med. 1980 Jun 1;151(6):1551-6 [6770028.001]
  • [Cites] Immunol Rev. 1980;51:337-57 [7000676.001]
  • [Cites] Nature. 1980 Oct 30;287(5785):853-5 [6776414.001]
  • [Cites] Cell. 1980 Dec;22(3):777-85 [6257398.001]
  • [Cites] Nature. 1981 Mar 19;290(5803):261-4 [7207618.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Feb;78(2):1181-4 [6940134.001]
  • [Cites] J Exp Med. 1981 Nov 1;154(5):1455-74 [6975347.001]
  • [Cites] Mol Immunol. 1981 Dec;18(12):1087-94 [6977702.001]
  • [Cites] Science. 1982 Aug 27;217(4562):801-6 [6285471.001]
  • [Cites] Cell. 1982 Aug;30(1):3-4 [6751559.001]
  • [Cites] Nature. 1982 Nov 18;300(5889):267-9 [6815536.001]
  • [Cites] Cell. 1982 Jul;29(3):953-60 [6185233.001]
  • [Cites] J Exp Med. 1983 Feb 1;157(2):705-19 [6185617.001]
  • [Cites] J Mol Biol. 1983 May 25;166(3):309-27 [6854649.001]
  • [Cites] Cell. 1983 Jun;33(2):389-96 [6134587.001]
  • [Cites] J Biol Chem. 1983 Jul 25;258(14):9017-23 [6190815.001]
  • [Cites] J Immunol. 1983 Oct;131(4):1808-15 [6352804.001]
  • [Cites] Nature. 1983 Nov 17-23;306(5940):239-42 [6316147.001]
  • [Cites] Cell. 1984 Jan;36(1):93-9 [6319012.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Mar;81(5):1509-13 [6231642.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jun;81(12):3765-9 [6610179.001]
  • [Cites] Science. 1984 Jun 22;224(4655):1312-6 [6427923.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Nov;81(21):6733-7 [6436820.001]
  • [Cites] Cell. 1985 Jul;41(3):677-83 [2988782.001]
  • [Cites] Cell. 1985 Jul;41(3):685-93 [2988783.001]
  • [Cites] J Biol Chem. 1986 Jan 5;261(1):453-9 [2934388.001]
  • [Cites] Mol Cell Biol. 1987 Jul;7(7):2631-5 [3039352.001]
  • [Cites] Science. 1988 May 27;240(4856):1169-76 [3131876.001]
  • [Cites] Cell. 1988 Sep 9;54(6):738-40 [2900688.001]
  • [Cites] Science. 1988 Nov 11;242(4880):933-5 [3263702.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23):9312-6 [3143116.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Mar;86(5):1603-7 [2466296.001]
  • [Cites] Oncogene. 1991 Mar;6(3):439-44 [2011398.001]
  • (PMID = 18982163.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 126
  • [Other-IDs] NLM/ PMC2575728
  •  go-up   go-down


18. Liozon E, Loustaud V, Fauchais AL, Soria P, Ly K, Ouattara B, Rhaiem K, Nadalon S, Vidal E: Concurrent temporal (giant cell) arteritis and malignancy: report of 20 patients with review of the literature. J Rheumatol; 2006 Aug;33(8):1606-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The time between diagnosis of TA and that of malignancy averaged 3.5 months (synchronous diagnoses in 27 patients).
  • Various locations of cancers were found, particularly the gastrointestinal tract (9 cases); blood malignancies accounted for 45% of cases (lymphoid disorder in 9, myelodysplastic syndrome in 11, chronic myelogenous leukemia in 1).
  • In our patients, logistic regression analysis failed to demonstrate differences between those with and without malignancy, except for a higher frequency of rheumatic involvement in the former group (60% vs 30%; p = 0.01).
  • CONCLUSION: Concurrent malignancy in TA is not a rare finding, being observed in up to 7.4% of the cases.

  • Genetic Alliance. consumer health - Temporal arteritis.
  • MedlinePlus Health Information. consumer health - Giant Cell Arteritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16832846.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Glucocorticoids
  •  go-up   go-down


19. Wang TT, Chen ZX, Cen JN, He J, Sheng HJ, Yao L: [Expression of growth-factor independence 1 in patients with leukemia and its significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug;18(4):834-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of growth-factor independence 1 in patients with leukemia and its significance].
  • This study was purposed to investigate the expression of the growth-factor independence 1 (GFI1) in patients with leukemia and its clinical significance.
  • Bone marrow mononuclear cells were obtained from 65 newly diagnosed leukemia patients including 24 acute myeloid leukemia (AML), 18 chronic myelogenous leukemia (CML), 6 acute lymphoblastic leukemia (ALL), 17 blast crisis of chronic myelogenous leukemia and 13 patients with iron deficiency anemia (IDA) were used as controls.
  • The results showed that gene expression of gene gfi1 in leukemia patients was obviously higher than that in controls and the difference was statistically significant (p < 0.01), in which the expression of gene gfi1 in newly diagnosed CML patients was higher than that in newly diagnosed AML, newly diagnosed ALL, CML-BCP patients and the difference was significant (p < 0.01).
  • Expression of gene gfi1 in lymphocytic blast crisis of CML was higher than that in nonlymphocytic blast crisis of CML, and the difference was significant.
  • It is concluded that gene gfi1 may play an important role in leukemia, especially in CML incidence and progression.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20723283.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / GFI1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


20. Yasukawa M: [Immunotherapy and cell therapy for myeloid leukemia]. Nihon Rinsho; 2009 Oct;67(10):1938-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunotherapy and cell therapy for myeloid leukemia].
  • Recently, various leukaemia-associated antigens that are recognized by CTL in the context of HLA class I molecules have been identified.
  • Here, the current status and future feasibility of cellular immunotherapy for leukemia are discussed.
  • [MeSH-major] Cell- and Tissue-Based Therapy / methods. Immunotherapy / methods. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19860194.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Antigen, T-Cell; 0 / TEL-AML1 fusion protein; 0 / Vaccines, Subunit; 0 / WT1 Proteins; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.4.21.76 / Myeloblastin
  • [Number-of-references] 20
  •  go-up   go-down


21. Vey N, Giles F: Cloretazine for the treatment of acute myeloid leukemia. Expert Rev Anticancer Ther; 2006 Mar;6(3):321-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cloretazine for the treatment of acute myeloid leukemia.
  • Phase I studies have shown myelosuppression to be the dose limiting toxicity in both solid tumors and leukemias.
  • A large Phase II study of single agent cloretazine (600 mg/m2) confirmed its activity in patients with relapsed acute myeloid leukemia, and in elderly patients with previously untreated acute myeloid leukemia or myelodysplastic syndrome.
  • Cloretazine can be safely combined with cytarabine, and this combination regimen is currently being tested in a large Phase III study in patients with relapsed acute myeloid leukemia.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hydrazines / therapeutic use. Leukemia, Myeloid / drug therapy. Sulfonamides / therapeutic use
  • [MeSH-minor] Acute Disease. Clinical Trials as Topic. Humans

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16503849.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hydrazines; 0 / Sulfonamides; 14J2G0U3NQ / laromustine
  • [Number-of-references] 65
  •  go-up   go-down


22. Mishra S, Zhang B, Cunnick JM, Heisterkamp N, Groffen J: Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells. Cancer Res; 2006 May 15;66(10):5387-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
  • Around 20% of patients with acute lymphoblastic leukemia are Philadelphia chromosome positive (Ph-positive acute lymphoblastic leukemia) and express the Bcr/Abl tyrosine kinase.
  • Treatment with the tyrosine kinase inhibitor Imatinib is currently standard for chronic myelogenous leukemia, which is also caused by Bcr/Abl.
  • However, Imatinib has shown limited efficacy for treating Ph-positive acute lymphoblastic leukemia.
  • In our study, we have investigated the effect of Imatinib therapy on murine P190 Bcr/Abl lymphoblastic leukemia cells.
  • Therefore, therapy for Ph-positive acute lymphoblastic leukemia, aimed at interfering with the protective effect of stroma in combination with Imatinib, could be of benefit for the eradication of the leukemic cells.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Fusion Proteins, bcr-abl / biosynthesis. Leukemia, Lymphoid / drug therapy. Piperazines / pharmacology. Pyrimidines / pharmacology

  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707466.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 90321
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Cxcl12 protein, mouse; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


23. Yang ZY, Huang H, Tang JH, Yu H, Wang YD, Xiang XY: [GPI-PLD gene exon14 polymorphisms of leucocyte in peripheral blood from healthy persons and leukemia patients]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Feb;31(1):28-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [GPI-PLD gene exon14 polymorphisms of leucocyte in peripheral blood from healthy persons and leukemia patients].
  • OBJECTIVE: To analyze the polymorphisms of glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD) gene exon 14, GPI-PLD activity of leucocyte in the peripheral blood,and the relationship in leukemia patients of Han nationality in Hunan.
  • METHODS: Both 96 leukemia patients and 96 healthy persons of Han nationality in Hunan were researched [including 48 acute non-lymphocytic leukaemia (ANLL) patients as group A, 31 acute lymphoblastic leukaemia (ALL) patients as group B, 12 chronic granulocytic leukaemia (CML) patients as group C, 5 chronic lymphocytic leukaemia (CLL) patients as group D].
  • RESULTS: There were four variations in the coverage of GPI-PLD gene exon 14 of leukemia patients and healthy persons.
  • The total various frequency in leukemia patient and healthy person, which was determined by SSCP, was 28.12% and 20.83%.
  • On the basis of the percentage of GPI-anchored PLAP conversion, the leucocyte GPI-PLD activities of the 96 leukemia patients were measured.
  • CONCLUSION: Leukocyte GPI-PLD gene in the peripheral blood, which belongs to healthy persons and leukemia patients of Han nationality in Hunan, is polymorphism.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myeloid, Acute / genetics. Phospholipase D / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Base Sequence. Exons / genetics. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Male. Middle Aged. Molecular Sequence Data. Point Mutation. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16562670.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 3.1.4.4 / Phospholipase D; EC 3.1.4.50 / glycoprotein phospholipase D
  •  go-up   go-down


24. Cornet AD, Issa AI, van de Loosdrecht AA, Ossenkoppele GJ, Strack van Schijndel RJ, Groeneveld AB: Sequential organ failure predicts mortality of patients with a haematological malignancy needing intensive care. Eur J Haematol; 2005 Jun;74(6):511-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: From a total of 58 patients (n = 47 with acute myelogenous leukaemia or non-Hodgkin lymphoma), admitted into ICU mostly because of respiratory insufficiency, sepsis, shock or combinations, 36 patients had died during their stay in the ICU.
  • [MeSH-major] Critical Care. Hospital Mortality. Leukemia, Myeloid, Acute / mortality. Lymphoma, Non-Hodgkin / mortality. Multiple Organ Failure / mortality

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Critical Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15876255.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


25. Jastaniah W, Harmatz P, Pakbaz Z, Fischer R, Vichinsky E, Walters MC: Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies. Pediatr Blood Cancer; 2008 Feb;50(2):319-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies.
  • BACKGROUND: While it is appropriate to treat transfusional iron overload to limit end-organ injury after bone marrow transplantation (BMT) for beta-thalassemia major (TM), this approach after BMT for sickle cell disease (SCD) and hematological malignancies has not been studied.
  • PROCEDURE: Fifteen children with SCD (n = 4), TM (n = 6), or acute myelogenous leukemia (AML, n = 5) underwent HLA-identical sibling BMT between 2000 and 2003.
  • Hepatic veno-occlusive disease (VOD) developed in 5 of 15 patients.
  • Changes in LIC were minimal in non-phlebotomized patients (P = 0.02).
  • CONCLUSION: Iron biomarkers demonstrated significant iron overload before BMT in patients with malignant and non-malignant disorders.
  • [MeSH-major] Anemia, Sickle Cell / therapy. Bone Marrow Transplantation / adverse effects. Iron Overload / etiology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Liver Diseases / metabolism. beta-Thalassemia / therapy


26. Burton C, Marin D, Apperley J: Personalized medical treatment strategies for patients with chronic myeloid leukemia. Expert Rev Anticancer Ther; 2005 Apr;5(2):343-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Personalized medical treatment strategies for patients with chronic myeloid leukemia.
  • Management of patients with chronic myeloid leukemia has become increasingly difficult over the last few years since there are a variety of treatment options available.
  • To facilitate this, assessment of an individual patient's disease in terms of status, tempo and response to initial treatment needs to be determined.
  • This review article discusses the current treatment options in the management of chronic myeloid leukemia, the factors that influence management decisions and suggests how treatment for the individual patient may be tailored whilst involving the patient in the decision-making process.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Patient Care Planning


27. Cooley L, Spelman D, Thursky K, Slavin M: Infection with Scedosporium apiospermum and S. prolificans, Australia. Emerg Infect Dis; 2007 Aug;13(8):1170-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Scedosporium apiospermum and S. prolificans are fungi of increasing clinical importance, particularly in persons with underlying diseases.
  • We reviewed the records of 59 patients in Australia from whom Scedosporium spp. were isolated from June 30, 1997, through December 31, 2003. S. apiospermum was isolated predominantly from the respiratory tracts of 28 of 31 patients with underlying lung diseases and resulted in 2 infections and 1 death.
  • The annual number of S. apiospermum isolates remained constant. S. prolificans was isolated from 28 patients only after November 1999.
  • Eight patients with acute myeloid leukemia or hematopoietic stem cell transplants had invasive infection; 4 had fungemia and 6 died from infection. S. prolificans caused locally invasive infection in 2 immunocompetent patients and was found in the respiratory tract of 18 patients with underlying respiratory disease but did not cause fungemia or deaths in these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Clin Microbiol Infect Dis. 2000 Jan;19(1):53-6 [10706182.001]
  • [Cites] Mycoses. 2001;44(7-8):321-5 [11714069.001]
  • [Cites] Clin Infect Dis. 2000 Sep;31(3):673-7 [11017814.001]
  • [Cites] Clin Infect Dis. 2002 Jan 1;34(1):7-14 [11731939.001]
  • [Cites] Clin Infect Dis. 2002 Feb 15;34(4):467-76 [11797173.001]
  • [Cites] J Infect. 2001 Oct;43(3):210-2 [11798262.001]
  • [Cites] Transpl Infect Dis. 2001 Dec;3(4):189-94 [11844150.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 May;21(5):938-9 [12062297.001]
  • [Cites] J Med Microbiol. 2002 Nov;51(11):924-8 [12448675.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Jan;47(1):106-17 [12499177.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2003 Feb;22(2):111-3 [12627286.001]
  • [Cites] J Clin Microbiol. 2003 Aug;41(8):3981-5 [12904435.001]
  • [Cites] Med Mycol. 2003 Aug;41(4):293-300 [12964722.001]
  • [Cites] Eye (Lond). 2003 Oct;17(7):841-3 [14528249.001]
  • [Cites] Mycoses. 2003 Dec;46(11-12):524-6 [14641629.001]
  • [Cites] Mayo Clin Proc. 2004 May;79(5):707-8 [15132423.001]
  • [Cites] Clin Infect Dis. 2004 Sep 1;39(5):743-6 [15356792.001]
  • [Cites] Clin Microbiol Infect. 2004 Oct;10(10):922-5 [15373888.001]
  • [Cites] Mayo Clin Proc. 1985 Aug;60(8):531-7 [3894816.001]
  • [Cites] J Clin Microbiol. 1988 Mar;26(3):498-503 [3356789.001]
  • [Cites] Lancet. 1991 Apr 13;337(8746):867-72 [1672966.001]
  • [Cites] Mycoses. 1991 Jan-Feb;34(1-2):1-18 [1922184.001]
  • [Cites] Clin Infect Dis. 1992 May;14(5):1027-33 [1534693.001]
  • [Cites] Medicine (Baltimore). 1997 Jul;76(4):256-65 [9279332.001]
  • [Cites] Clin Infect Dis. 1998 Dec;27(6):1437-41 [9868657.001]
  • [Cites] Clin Infect Dis. 1999 Jul;29(1):212-3 [10433595.001]
  • [Cites] Clin Infect Dis. 2005 Jan 1;40(1):89-99 [15614697.001]
  • [Cites] J Clin Microbiol. 2005 Feb;43(2):973-7 [15695722.001]
  • [Cites] Am J Ophthalmol. 2005 Feb;139(2):370-3 [15734012.001]
  • [Cites] Med Mycol. 2005 May;43(3):253-60 [16010852.001]
  • [Cites] J Clin Microbiol. 2005 Oct;43(10):4930-42 [16207945.001]
  • [Cites] J Infect. 2006 Jan;52(1):67-74 [16368463.001]
  • [Cites] Med Mycol. 2006 Jun;44(4):295-327 [16772225.001]
  • [Cites] Clin Infect Dis. 2006 Dec 15;43(12):1580-4 [17109292.001]
  • [Cites] J Clin Microbiol. 2001 Jan;39(1):47-50 [11136746.001]
  • [Cites] Clin Infect Dis. 2001 Jun 1;32(11):E158-65 [11340550.001]
  • [Cites] Lancet. 2001 Apr 21;357(9264):1267-8 [11418156.001]
  • [Cites] Ann Hematol. 2000 Jun;79(6):340-4 [10901616.001]
  • (PMID = 17953087.001).
  • [ISSN] 1080-6040
  • [Journal-full-title] Emerging infectious diseases
  • [ISO-abbreviation] Emerging Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2828065
  •  go-up   go-down


28. Chen W, Yu YS, Liu YH, Sheen JM, Hsiao CC: Nail changes associated with chemotherapy in children. J Eur Acad Dermatol Venereol; 2007 Feb;21(2):186-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A cross-sectional study was performed on 30 paediatric patients (aged 1-17, mean 8.3 years), including 11 with acute lymphoblastic leukaemia, five with acute myeloid leukaemia, and others.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Nail Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17243953.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


29. Kantarjian HM, Cortes J, La Rosée P, Hochhaus A: Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer; 2010 Mar 15;116(6):1419-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
  • Identification of BCR-ABL as the defining leukemogenic event in chronic myelogenous leukemia (CML) revolutionized the treatment of the disease.
  • However, for patients with primary resistance to imatinib, hematologic disease recurrence, or emergent BCR-ABL kinase domain mutations, imatinib dose escalation may not be sufficient to control the disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myeloid, Chronic-Phase / drug therapy. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Thiazoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20120030.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl; RBZ1571X5H / Dasatinib
  • [Number-of-references] 94
  •  go-up   go-down


30. Su JY, Chang CK, Zhang X, Zhou LY, Song LQ, Xu L, Wu LY, He Q, Li X: [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr;17(2):459-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
  • This study was aimed to investigate the efficacy of moderate intensity regimen, CHG (homoharringtonine, cytarabine and granulocyte colony-stimulating factor (G-CSF)) on the patients with high-risk MDS or MDS-transformed acute myeloid leukemia.
  • The results showed that (1) 14 patients achieved complete remission (CR) (46.67 %) and 7 patients achieved partial remission (PR) (23.33 %) with one course of CHG regimen, total effective rate was 70%; 14 patient achieved CR (42.4%) and 9 patients achieved PR (27.3%) with one course of CAG regimen, total effective rate was 69.7%; 7 patient achieved CR (33.3%) and 3 patients achieved PR (9.1%) with one course of HA regimen, total effective rate was 42.4%.


31. Liu W, Lee HW, Liu Y, Wang R, Rodgers GP: Olfactomedin 4 is a novel target gene of retinoic acids and 5-aza-2'-deoxycytidine involved in human myeloid leukemia cell growth, differentiation, and apoptosis. Blood; 2010 Dec 2;116(23):4938-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactomedin 4 is a novel target gene of retinoic acids and 5-aza-2'-deoxycytidine involved in human myeloid leukemia cell growth, differentiation, and apoptosis.
  • Clinical application of retinoic acids (RAs) and demethylation agents has proven to be effective in treating certain myeloid leukemia patients.
  • In this study, we identified olfactomedin 4 (OLFM4), a myeloid-lineage-specific gene from the olfactomedin family, as a novel target gene for RAs and the demethylation agent, 5-aza-2'-deoxycytidine.
  • Conversely, down-regulation of endogenous OLFM4 in acute myeloid leukemia-193 cells compromised ATRA-induced growth inhibition, differentiation, and apoptosis.
  • Overexpression of OLFM4 in HL-60 cells inhibited constitutive and ATRA-induced phosphorylation of the eukaryote initiation factor 4E-binding protein 1 (4E-BP1), whereas down-regulation of OLFM4 protein in acute myeloid leukemia-193 cells increased 4E-BP1 phosphorylation, suggesting that OLFM4 is a potent upstream inhibitor of 4E-BP1 phosphorylation/deactivation.
  • Thus, our study demonstrates that OLFM4 plays an important role in myeloid leukemia cellular functions and induction of OLFM4-mediated effects may contribute to the therapeutic value of ATRA.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2000 Mar 1;19(5):1087-97 [10698949.001]
  • [Cites] Int J Cancer. 2009 Nov 15;125(10):2383-92 [19670418.001]
  • [Cites] Mol Cell Biol. 2000 Dec;20(23):8983-95 [11073997.001]
  • [Cites] Gene. 2002 Jan 23;283(1-2):83-93 [11867215.001]
  • [Cites] Semin Cancer Biol. 2002 Oct;12(5):347-57 [12191634.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4298-302 [12393590.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2474-81 [15059901.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4294-301 [14962908.001]
  • [Cites] Mol Cell Biol. 2004 Oct;24(19):8447-56 [15367666.001]
  • [Cites] Blood. 1988 Aug;72(2):567-72 [3165295.001]
  • [Cites] Curr Opin Cell Biol. 1993 Dec;5(6):955-60 [7907492.001]
  • [Cites] Mol Cell Biol. 1995 Jul;15(7):3540-51 [7791761.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4296-307 [9834236.001]
  • [Cites] Cell. 1999 Jan 22;96(2):235-44 [9988218.001]
  • [Cites] EMBO J. 1999 Mar 1;18(5):1223-34 [10064589.001]
  • [Cites] Clin Exp Metastasis. 1998 Jul;16(5):471-9 [10091942.001]
  • [Cites] J Immunol. 1999 Mar 15;162(6):3491-7 [10092805.001]
  • [Cites] J Biol Chem. 1999 May 14;274(20):14295-305 [10318851.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1422-37 [10364159.001]
  • [Cites] Mol Cell Biol. 2005 Apr;25(7):2558-72 [15767663.001]
  • [Cites] Gastric Cancer. 2005;8(2):86-94 [15864715.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S4-11 [16341240.001]
  • [Cites] Exp Cell Res. 2006 Jun 10;312(10):1785-97 [16566923.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):315-20 [17270020.001]
  • [Cites] Exp Hematol. 2007 Apr;35(4):572-8 [17379067.001]
  • [Cites] Histopathology. 2007 Aug;51(2):157-65 [17650212.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2302-8 [17596541.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1041-9 [18281536.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Apr 18;368(4):983-9 [18280804.001]
  • [Cites] Cell. 2008 Sep 5;134(5):854-65 [18775317.001]
  • [Cites] Br J Haematol. 2008 Nov;143(3):421-32 [18764868.001]
  • [Cites] Exp Cell Res. 2008 Dec 10;314(20):3701-11 [18930044.001]
  • [Cites] Int J Cancer. 2008 Dec 15;123(12):2856-64 [18798264.001]
  • [Cites] Mol Neurobiol. 2009 Oct;40(2):122-38 [19554483.001]
  • [Cites] Curr Top Microbiol Immunol. 2000;249:135-64 [10802943.001]
  • (PMID = 20724538.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antineoplastic Agents; 0 / EIF4EBP1 protein, human; 0 / OLFM4 protein, human; 0 / Phosphoproteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5688UTC01R / Tretinoin; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC3012588
  •  go-up   go-down


32. El Fekih L, Hmaied W, Elhif S, Miled W, Sakka S: [Chronic myeloid leukemia revealed by bilateral occlusion of the retinal central vein]. Tunis Med; 2008 Oct;86(10):937-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chronic myeloid leukemia revealed by bilateral occlusion of the retinal central vein].
  • [Transliterated title] Occlusion bilatérale de la veine centrale de rétine révélant une leucémie myéloïde chronique.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Retinal Vein Occlusion / etiology


33. Krishnan B, Morgan GJ: Non-Hodgkin lymphoma secondary to cancer chemotherapy. Cancer Epidemiol Biomarkers Prev; 2007 Mar;16(3):377-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma secondary to cancer chemotherapy.
  • Therapy-related acute myeloid leukemia has been frequently documented in these patient cohorts, and its biology well studied.
  • Recognition of secondary non-Hodgkin lymphoma as a cause of significant morbidity and mortality in these patients is equally important.
  • The patterns of incidence and latency of secondary lymphomas is distinct from that of myeloid malignancies and other solid cancers.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Lymphoma, Non-Hodgkin / chemically induced. Neoplasms / drug therapy. Neoplasms, Second Primary / chemically induced

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17372233.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 24
  •  go-up   go-down


34. Sahin F, Celik HA, Aydin HH, Oktem G, Omay SB, Saydam G: The interaction between taxoids and serine/threonine protein phosphatase activities during taxan-induced apoptosis of HL 60 leukemic cells. Hematology; 2008 Aug;13(4):215-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The interaction between taxoids and serine/threonine protein phosphatase activities during taxan-induced apoptosis of HL 60 leukemic cells.
  • Several studies have investigated their potential in the treatment of myeloid malignancies.
  • Potential use of specific protein phosphatase inhibitors or activators in combination with taxoids will open new windows in the treatment of myeloid leukemias.

  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18796247.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; EC 3.1.3.16 / Phosphoprotein Phosphatases; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


35. Andreeva SV, Drozdova VD, Ponochevnaia EV, Kavardakova NV: [Rearrangements of chromosome 9 in different hematological neoplasia]. Tsitol Genet; 2008 Sep-Oct;42(5):72-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The frequencies of chromosome 9 abnormalities in children with hematological neoplasia have constituted: 25/112 in acute lymphoblastic leukemia (ALL), 10/83--in acute myeloid leukemia (AML), 3/20--in refractory anemia (RA).
  • Multidrug resistance and disease progression during chemotherapy were noted in t (9;22).
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 9 / genetics. Leukemia, Myeloid, Acute / genetics. Myelodysplastic Syndromes / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic


36. Löwenberg B: Diagnosis and prognosis in acute myeloid leukemia--the art of distinction. N Engl J Med; 2008 May 1;358(18):1960-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and prognosis in acute myeloid leukemia--the art of distinction.
  • [MeSH-major] Gene Expression. Leukemia, Myeloid, Acute / genetics. MicroRNAs / metabolism. RNA, Neoplasm / metabolism
  • [MeSH-minor] CCAAT-Enhancer-Binding Protein-alpha / genetics. Gene Expression Regulation, Leukemic. Genetic Markers. Genotype. Humans. Mutation. Nuclear Proteins / genetics. Prognosis. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] N Engl J Med. 2008 May 1;358(18):1919-28 [18450603.001]
  • [CommentOn] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]
  • (PMID = 18450608.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Protein-alpha; 0 / Genetic Markers; 0 / MicroRNAs; 0 / Nuclear Proteins; 0 / RNA, Neoplasm; 117896-08-9 / nucleophosmin; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


37. Groot OA, Trof RJ, Girbes AR, Swart NL, Beishuizen A: Acute refractory hyperkalaemia and fatal cardiac arrest related to administration of liposomal amphotericin B. Neth J Med; 2008 Nov;66(10):433-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 36-year-old male with acute myeloid leukaemia was treated with liposomal amphotericin B for a breakthrough fungal infection with Absidia corymbifera during voriconazole and caspofungin therapy for invasive pulmonary aspergillosis.
  • [MeSH-minor] Absidia / isolation & purification. Adult. Fatal Outcome. Humans. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / microbiology. Male. Mucormycosis / drug therapy

  • MedlinePlus Health Information. consumer health - Cardiac Arrest.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011270.001).
  • [ISSN] 0300-2977
  • [Journal-full-title] The Netherlands journal of medicine
  • [ISO-abbreviation] Neth J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


38. Hsiao PC, Liu MC, Chen LM, Tsai CY, Wang YT, Chen J, Hsu LS: Promoter methylation of p16 and EDNRB gene in leukemia patients in Taiwan. Chin J Physiol; 2008 Feb 29;51(1):27-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter methylation of p16 and EDNRB gene in leukemia patients in Taiwan.
  • In this study, we have identified the methylation frequency of p16 and endothelin receptor type B (EDNRB) of 26 leukemia patients and 8 randomly selected normal blood donors in Taiwan.
  • Promoter methylation of p16 was detected in 85% of acute lymphocytic leukemia (ALL), 83% in acute myeloid leukemia (AML) whereas no methylation was detected in chronic myeloid leukemia (CML) in blast crisis.
  • Taken together, aberrant methylation of p16 and EDNRB was highly prevalent in leukemia patients in Taiwan.
  • [MeSH-major] DNA Methylation. Genes, p16. Leukemia / genetics. Receptor, Endothelin B / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18551992.001).
  • [ISSN] 0304-4920
  • [Journal-full-title] The Chinese journal of physiology
  • [ISO-abbreviation] Chin J Physiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Receptor, Endothelin B
  •  go-up   go-down


39. Kurosu T, Ohki M, Wu N, Kagechika H, Miura O: Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res; 2009 May 1;69(9):3927-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the BCR/ABL tyrosine kinase inhibitor imatinib is highly effective for treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia, relapse with emerging imatinib resistance mutations in the BCR/ABL kinase domain poses a significant problem.
  • Sorafenib-induced apoptosis in these cells and Ph+ leukemic cells was synergistically enhanced by rottlerin, bortezomib, or ABT-737 and inhibited by the pan-caspase inhibitor BOC-d-fmk or the overexpression of Bcl-XL.
  • Thus, sorafenib may provide an effective therapeutic measure to treat Ph+ leukemias, particularly those expressing the T315I mutant, which is totally resistant to imatinib and the second generation BCR/ABL inhibitors.
  • [MeSH-major] Apoptosis / drug effects. Benzenesulfonates / pharmacology. Fusion Proteins, bcr-abl / antagonists & inhibitors. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Mitochondria / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyridines / pharmacology

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19366808.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABT-737; 0 / Acetophenones; 0 / Benzamides; 0 / Benzenesulfonates; 0 / Benzopyrans; 0 / Biphenyl Compounds; 0 / Boronic Acids; 0 / Interleukin-3; 0 / Nitrophenols; 0 / Phenylurea Compounds; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrazines; 0 / Pyridines; 0 / Pyrimidines; 0 / Sulfonamides; 25X51I8RD4 / Niacinamide; 69G8BD63PP / Bortezomib; 8A1O1M485B / Imatinib Mesylate; 9ZOQ3TZI87 / sorafenib; E29LP3ZMUH / rottlerin; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.4.22.- / Caspases
  •  go-up   go-down


40. Roy AM, Tiwari KN, Parker WB, Secrist JA 3rd, Li R, Qu Z: Antiangiogenic activity of 4'-thio-beta-D-arabinofuranosylcytosine. Mol Cancer Ther; 2006 Sep;5(9):2218-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is a structural analogue of cytarabine (araC), a clinically used drug in the treatment of acute myelogenous leukemia, which has no or very limited efficacy against solid tumors.
  • The findings of this study show a role of T-araC in antiangiogenesis and suggest that T-araC combines antiproliferative and antiangiogenic activity in one molecule for a dual mechanism of drug action to achieve the excellent in vivo efficacy against several solid tumors.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16985055.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4'-thio-arabinofuranosylcytosine; 0 / Angiogenesis Inhibitors; 0 / Arabinonucleosides; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


41. Güven GS, Tarkan Argüden Y, Öngören Ş, Deviren A, Aydın Y, Hacıhanefioglu S: t(1;3)(p36;p21): presentation of a patient with MDS/AML (M2) and review of the literature. Turk J Haematol; 2006 Jun 5;23(2):115-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] t(1;3)(p36;p21): presentation of a patient with MDS/AML (M2) and review of the literature.
  • t(1;3)(p36;p21) is a recurrent reciprocal translocation found in a subset of myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) characterized by trilineage dysplasia, especially dysmegakaryopoiesis and poor prognosis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265294.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


42. Rao S, Langston A, Galt JR, Halkar RK: Extramedullary acute myeloid leukemia and the use of FDG-PET/CT. Clin Nucl Med; 2009 Jun;34(6):365-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary acute myeloid leukemia and the use of FDG-PET/CT.
  • [MeSH-major] Fluorodeoxyglucose F18. Leukemia, Myeloid, Acute / radiography. Leukemia, Myeloid, Acute / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19487847.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


43. Boyd EM, Bench AJ, Vaghela KJ, Campbell GN, Chowdhury FB, Gudgin EJ, Scott MA, Erber WN: Therapy-related acute myeloid leukaemia with t(8;16)(p11;p13);MOZ-CBP and polymorphisms in detoxifying and DNA repair genes. Leukemia; 2009 Jun;23(6):1164-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myeloid leukaemia with t(8;16)(p11;p13);MOZ-CBP and polymorphisms in detoxifying and DNA repair genes.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Neoplasms, Second Primary / genetics. Oncogene Proteins, Fusion / genetics. Polymorphism, Genetic. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19158836.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MOZ-CBP fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


44. Maserati E, Pressato B, Valli R, Minelli A, Sainati L, Patitucci F, Marletta C, Mastronuzzi A, Poli F, Lo Curto F, Locatelli F, Danesino C, Pasquali F: The route to development of myelodysplastic syndrome/acute myeloid leukaemia in Shwachman-Diamond syndrome: the role of ageing, karyotype instability, and acquired chromosome anomalies. Br J Haematol; 2009 Apr;145(2):190-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The route to development of myelodysplastic syndrome/acute myeloid leukaemia in Shwachman-Diamond syndrome: the role of ageing, karyotype instability, and acquired chromosome anomalies.
  • An investigation of 22 new patients with Shwachman-Diamond syndrome (SDS) and the follow-up of 14 previously reported cases showed that (i) clonal chromosome changes of chromosomes 7 and 20 were present in the bone marrow (BM) of 16 out of 36 cases, but if non-clonal changes were taken into account, the frequency of anomalies affecting these chromosomes was 20/36: a specific SDS karyotype instability was thus confirmed;.
  • (iii) the deletion del(20)(q11) involved the minimal region of deletion typical of myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML);.
  • (iv) only one patient developed MDS, during the rapid expansion of a BM clone with a chromosome 7 carrying additional material on the short arms;.
  • [MeSH-major] Aging / genetics. Chromosome Aberrations. Leukemia, Myeloid, Acute / genetics. Myelodysplastic Syndromes / genetics
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Cells / ultrastructure. Child. Child, Preschool. Chromosome Breakage. Chromosomes, Human, Pair 20. Chromosomes, Human, Pair 7. DNA Mutational Analysis. Disease Progression. Female. Follow-Up Studies. Humans. In Situ Hybridization, Fluorescence. Isochromosomes. Karyotyping. Male. Proteins / genetics. Young Adult


45. Wong O, Harris F, Yiying W, Hua F: A hospital-based case-control study of acute myeloid leukemia in Shanghai: analysis of personal characteristics, lifestyle and environmental risk factors by subtypes of the WHO classification. Regul Toxicol Pharmacol; 2009 Dec;55(3):340-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A hospital-based case-control study of acute myeloid leukemia in Shanghai: analysis of personal characteristics, lifestyle and environmental risk factors by subtypes of the WHO classification.
  • OBJECTIVES: The objectives are (1) to investigate and identify potential risk factors (personal characteristics, lifestyle and environmental factors) of acute myeloid leukemia (AML), and (2) to explore the relationships between potential risk factors and AML subtypes according to the World Health Organization (WHO) classification of myeloid neoplasms.
  • Some risk factors applied to all or several subtypes (such as low-level education and living on a farm), while others were limited to one or two specific subtypes (such as home/office renovation and acute promyelocytic leukemia).
  • An inverse association was found between BMI and overall AML or the sub-category "AML not otherwise categorized", whereas a positive association between BMI and the subtype acute promyelocytic leukemia was detected.
  • An unexpected finding was the association between the use of traditional Chinese medicines and a reduced risk of AML in general as well as several major subtypes.
  • Some of the risk factors were subtype-specific.
  • The difference in risk by subtype underscores the importance of investigating the etiologic commonality and heterogeneity of AML by subtype in epidemiologic research.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Medicine, Chinese Traditional / methods. Occupational Exposure / adverse effects


46. Amorim MR, Zanrosso CW, Magalhães IQ, Pereira SC, Figueiredo A, Emerenciano M, Pinheiro VR, d'Andréa ML, Orioli IM, Koifman S, Pombo-de-Oliveira MS: MTHFR 677C--&gt;T and 1298A--&gt;C polymorphisms in children with Down syndrome and acute myeloid leukemia in Brazil. Pediatr Hematol Oncol; 2008 Dec;25(8):744-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MTHFR 677C-->T and 1298A-->C polymorphisms in children with Down syndrome and acute myeloid leukemia in Brazil.
  • Down syndrome (DS) is an important risk factor associated with acute leukemia (AL).
  • The authors have conducted a study to test whether 677C-->T and/or 1298A-->C polymorphisms of MTHFR would play an additional role in susceptibility of acute myeloid leukemia (AML) in DS children.
  • Genetic polymorphisms determination was carried out in 248 samples from healthy individuals as controls and a total of 115 DS children (65 without leukemia and 50 with AML).
  • [MeSH-major] Down Syndrome / genetics. Leukemia, Myeloid, Acute / genetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic
  • [MeSH-minor] Brazil / epidemiology. Case-Control Studies. Child. Child, Preschool. Female. Genetic Predisposition to Disease. Genotype. Humans. Infant. Infant, Newborn. Male. Molecular Epidemiology


47. Chou WC, Tang JL, Lin LI, Yao M, Tsay W, Chen CY, Wu SJ, Huang CF, Chiou RJ, Tseng MH, Lin DT, Lin KH, Chen YC, Tien HF: Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res; 2006 Mar 15;66(6):3310-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution.
  • Nucleophosmin (NPM) mutations have been found in a significant proportion of adults with de novo acute myeloid leukemia (AML), especially in those of a normal karyotype.
  • In this study, NPM mutations were analyzed in 173 Chinese patients of de novo AML, including adults and children.
  • Moreover, the findings that NPM mutations are stable during disease evolution and closely associated with disease status make it a potential marker for monitoring minimal residual disease.
  • [MeSH-major] Leukemia, Myeloid / genetics. Mutation. Nuclear Proteins / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Age Factors. Aged. Amino Acid Sequence. Base Sequence. Child. Child, Preschool. Disease Progression. Exons. Female. Humans. Immunophenotyping. Infant. Male. Middle Aged. Molecular Sequence Data

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540685.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin
  •  go-up   go-down


48. Montenegro DE, Franklin T, Moscinski LC, Zuckerman KS, Hu XT: TGFbeta inhibits GM-CSF-induced phosphorylation of ERK and MEK in human myeloid leukaemia cell lines via inhibition of phosphatidylinositol 3-kinase (PI3-k). Cell Prolif; 2009 Feb;42(1):1-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TGFbeta inhibits GM-CSF-induced phosphorylation of ERK and MEK in human myeloid leukaemia cell lines via inhibition of phosphatidylinositol 3-kinase (PI3-k).
  • In this study, we investigated whether TGF-beta activates the ERK pathway and how TGFbeta communicates with the MAP kinase signals induced by a mitogen, in human myeloid leukaemia cells.
  • CONCLUSIONS: These studies thus indicate that TGFbeta does not activate the ERK pathway but turns off the GM-CSF-induced ERK signal via inhibition of the PI3-kinase-Akt pathway, in these human leukaemia cells.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr J. 1999 Aug;46(4):545-53 [10580747.001]
  • [Cites] Mol Cancer Ther. 2006 Jun;5(6):1452-8 [16818503.001]
  • [Cites] Oncogene. 2001 Oct 18;20(47):6840-50 [11687963.001]
  • [Cites] Hepatology. 2002 Jun;35(6):1360-71 [12029621.001]
  • [Cites] FASEB J. 2003 Aug;17(11):1576-8 [12824291.001]
  • [Cites] J Immunol. 1986 Dec 15;137(12):3855-60 [2878044.001]
  • [Cites] Cell. 1987 Feb 13;48(3):417-28 [2879636.001]
  • [Cites] Blood. 1987 Jul;70(1):192-9 [3496132.001]
  • [Cites] J Cell Physiol. 1989 Aug;140(2):323-34 [2663885.001]
  • [Cites] J Biol Chem. 1990 Nov 15;265(32):19812-7 [1700980.001]
  • [Cites] Blood. 1991 Jan 15;77(2):243-8 [1845931.001]
  • [Cites] Blood. 1992 Jun 1;79(11):2880-7 [1375118.001]
  • [Cites] Nature. 1992 Jul 30;358(6385):417-21 [1322500.001]
  • [Cites] Science. 1992 Sep 4;257(5075):1404-7 [1326789.001]
  • [Cites] Neuron. 1992 Oct;9(4):705-17 [1382473.001]
  • [Cites] Science. 1993 Apr 16;260(5106):315-9 [8385802.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8319-23 [8397401.001]
  • [Cites] Cell. 1993 Sep 24;74(6):1009-20 [8402878.001]
  • [Cites] Cell. 1995 Jan 27;80(2):179-85 [7834738.001]
  • [Cites] Blood. 1996 May 1;87(9):3669-75 [8611691.001]
  • [Cites] Cell. 1996 Dec 27;87(7):1215-24 [8980228.001]
  • [Cites] J Biol Chem. 1997 Jan 31;272(5):2896-900 [9006934.001]
  • [Cites] Genes Dev. 1997 Feb 15;11(4):492-503 [9042862.001]
  • [Cites] Mol Cell Biol. 1997 Apr;17(4):1947-58 [9121442.001]
  • [Cites] Leuk Res. 1998 Sep;22(9):817-26 [9716013.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):5333-8 [10026141.001]
  • [Cites] Exp Hematol. 1999 Apr;27(4):605-14 [10210318.001]
  • [Cites] Curr Vasc Pharmacol. 2005 Jan;3(1):55-61 [15638782.001]
  • [Cites] J Biol Chem. 2005 Mar 18;280(11):10870-6 [15657037.001]
  • [Cites] Exp Cell Res. 2005 Jul 1;307(1):231-46 [15922743.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 18;337(2):551-6 [16202975.001]
  • [Cites] Mol Pharmacol. 2006 Feb;69(2):597-607 [16288083.001]
  • [Cites] Cell Growth Differ. 2000 Apr;11(4):191-200 [10775036.001]
  • (PMID = 19143758.001).
  • [ISSN] 1365-2184
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R25 GM059244; United States / PHS HHS / / R25 G059244
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / Transforming Growth Factor beta; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ NIHMS554938; NLM/ PMC3928791
  •  go-up   go-down


49. Tran LM, Hyduke DR, Liao JC: Trimming of mammalian transcriptional networks using network component analysis. BMC Bioinformatics; 2010 Oct 13;11:511
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twelve of these TFs are involved in MAPK signaling or myeloid leukemia pathways defined in the KEGG database, or are known to physically interact with each other.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D137-40 [17202159.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D358-62 [17098935.001]
  • [Cites] J Clin Invest. 2008 Sep;118(9):3065-74 [18725988.001]
  • [Cites] Int J Hematol. 2000 Feb;71(2):153-8 [10745625.001]
  • [Cites] Pac Symp Biocomput. 2000;:455-66 [10902193.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10101-6 [10963673.001]
  • [Cites] Nat Genet. 2001 Feb;27(2):167-71 [11175784.001]
  • [Cites] Nat Genet. 2001 Mar;27(3):304-8 [11242113.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):4819-27 [11096091.001]
  • [Cites] Cell. 2002 Jan 11;108(1):57-70 [11792321.001]
  • [Cites] Bioinformatics. 2002 Jan;18(1):51-60 [11836211.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):10804-12 [11792711.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):147-58 [12957289.001]
  • [Cites] Genome Biol. 2003;4(11):R76 [14611662.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D303-6 [14681419.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15522-7 [14673099.001]
  • [Cites] Nat Cell Biol. 2004 Feb;6(2):97-105 [14743216.001]
  • [Cites] BMC Bioinformatics. 2004 Mar 18;5:31 [15113405.001]
  • [Cites] Nat Med. 2004 Jun;10(6):594-601 [15156201.001]
  • [Cites] Cell. 2004 Jun 11;117(6):713-20 [15186773.001]
  • [Cites] Nature. 2004 Sep 2;431(7004):99-104 [15343339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5100-4 [8389468.001]
  • [Cites] J Biol Chem. 1995 Apr 21;270(16):9454-8 [7721872.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5328-35 [9393757.001]
  • [Cites] Mol Cell. 2005 Jan 7;17(1):11-21 [15629713.001]
  • [Cites] Metab Eng. 2005 Mar;7(2):128-41 [15781421.001]
  • [Cites] Gene. 2005 Apr 25;350(1):89-98 [15794924.001]
  • [Cites] BMC Genomics. 2005;6:90 [15949038.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1801-7 [15886325.001]
  • [Cites] Bioinformatics. 2005 Nov 1;21(21):4033-8 [16144806.001]
  • [Cites] Bioinformatics. 2006 Aug 1;22(15):1886-94 [16766556.001]
  • [Cites] BMC Bioinformatics. 2006;7:290 [16762055.001]
  • [Cites] IEEE/ACM Trans Comput Biol Bioinform. 2005 Oct-Dec;2(4):289-301 [17044167.001]
  • [Cites] Bioinformatics. 2006 Dec 15;22(24):3040-6 [17060361.001]
  • [Cites] J Biol Chem. 2006 Dec 29;281(52):40341-53 [17071615.001]
  • [Cites] J Cell Biol. 2008 Feb 25;180(4):691-6 [18299344.001]
  • (PMID = 20942926.001).
  • [ISSN] 1471-2105
  • [Journal-full-title] BMC bioinformatics
  • [ISO-abbreviation] BMC Bioinformatics
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM076143
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2967563
  •  go-up   go-down


50. Kasukabe T, Okabe-Kado J, Kato N, Sassa T, Honma Y: Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res; 2005;7(6):R1097-110
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: We evaluated the growth-inhibitory effect of rapamycin plus various agents, including cotylenin A (a novel inducer of differentiation of myeloid leukaemia cells) to MCF-7 cells, using either MTT assay or trypan blue dye exclusion test.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1970 Jul 25;227(5256):379 [5428434.001]
  • [Cites] Exp Hematol. 2002 May;30(5):421-9 [12031648.001]
  • [Cites] Cancer Res. 1986 Mar;46(3):1239-43 [3455882.001]
  • [Cites] Cancer Res. 1991 May 15;51(10):2582-6 [1673636.001]
  • [Cites] Oncogene. 1991 Jun;6(6):917-28 [1906159.001]
  • [Cites] DNA Cell Biol. 1994 Jun;13(6):571-84 [8024701.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):27449-67 [11956189.001]
  • [Cites] Leuk Lymphoma. 2002 Jun;43(6):1169-78 [12152984.001]
  • [Cites] J Biol Chem. 2002 Aug 9;277(32):29069-77 [12021278.001]
  • [Cites] Mol Pharmacol. 2003 Mar;63(3):766-72 [12606787.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):2045-53 [12673209.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3659-66 [12839956.001]
  • [Cites] Leuk Res. 2003 Nov;27(11):1019-25 [12859995.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jul;80(1):23-37 [12889596.001]
  • [Cites] Curr Opin Pharmacol. 2003 Aug;3(4):371-7 [12901945.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4602-6 [12907638.001]
  • [Cites] Endocrinology. 2003 Oct;144(10):4562-74 [12959972.001]
  • [Cites] J Biol Chem. 2004 Jan 23;279(4):2737-46 [14576155.001]
  • [Cites] Front Biosci. 2004 Jan 1;9:192-200 [14766359.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):1013-23 [14871980.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(5):2181-9 [14966295.001]
  • [Cites] Breast Cancer Res Treat. 2004 May;85(1):53-63 [15039597.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jun;85(3):229-38 [15111761.001]
  • [Cites] J Mol Endocrinol. 2004 Jun;32(3):649-61 [15171706.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Oncogene. 1995 Nov 2;11(9):1921-8 [7478623.001]
  • [Cites] J Biol Chem. 1997 May 9;272(19):12650-61 [9139721.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 29;238(3):758-63 [9325163.001]
  • [Cites] Mol Cell Biol. 1998 Jul;18(7):3744-51 [9632757.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4634-41 [10493518.001]
  • [Cites] J Cell Physiol. 2005 Apr;203(1):85-93 [15372466.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):3-27 [15221985.001]
  • [Cites] J Cell Biochem. 1999 Dec;76(2):231-43 [10618640.001]
  • [Cites] Br J Haematol. 2001 Mar;112(3):697-705 [11260075.001]
  • [Cites] Anticancer Res. 2001 May-Jun;21(3B):1665-71 [11497245.001]
  • [Cites] Br J Haematol. 2001 Sep;114(4):814-21 [11564068.001]
  • [Cites] Endocr Relat Cancer. 2001 Sep;8(3):249-58 [11566616.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):8-12 [11782349.001]
  • [Cites] Curr Opin Investig Drugs. 2002 Feb;3(2):295-304 [12020063.001]
  • [Cites] Adv Enzyme Regul. 1984;22:27-55 [6382953.001]
  • (PMID = 16457690.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Diterpenes; 0 / cotylenin A; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC1410757
  •  go-up   go-down


51. Papenhausen PR, Griffin S, Tepperberg J: Oncogene amplification in transforming myelodysplasia. Exp Mol Pathol; 2005 Oct;79(2):168-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The MLL gene, located within band 11q23, has been shown to be involved in translocations with a large variety of reciprocal sites in both lymphoid and myeloid leukemia and has also been shown to undergo submicroscopic self-fusion/partial duplication.
  • The frequency and clinical correlations of MLL gene amplification in leukemia will need careful follow-up, since the frequently cryptic amplification described in these cases may not generally provoke confirmatory FISH studies.
  • Both genes also show a high degree of diversity of pathogenic mechanisms of leukemia evolution, including numerous reciprocal fusion genes in transformation to either AML or ALL and gain of function amplification.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. Core Binding Factor Alpha 2 Subunit. Female. Histone-Lysine N-Methyltransferase. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Myeloid-Lymphoid Leukemia Protein. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins / genetics

  • MedlinePlus Health Information. consumer health - Neural Tube Defects.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16026782.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Proto-Oncogene Proteins; 0 / RUNX1 protein, human; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


52. Han JS, Oh SY, Kim SH, Kwon HC, Hong SH, Han JY, Park KJ, Kim HJ: A case of pathologic splenic rupture as the initial manifestation of acute myeloid leukemia M2. Yonsei Med J; 2010 Jan;51(1):138-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of pathologic splenic rupture as the initial manifestation of acute myeloid leukemia M2.
  • A splenic rupture as the initial manifestation of acute myeloid leukemia is extremely rare.
  • In this study, we described a rare case of acute myeloid leukemia presenting principally as an acute abdomen due to a pathologic splenic rupture in a 35-year old male patient.
  • We can assert that a pathologic splenic rupture in hematologic diseases is a potentially life-threatening complication, which necessitates immediate operative intervention.
  • The oncologist should be aware of this rare initial presentation of acute myeloid leukemia (AML) M2, as the condition generally necessitates a prompt splenectomy.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Splenic Rupture / diagnosis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jan 15;88(2):480-90 [10640983.001]
  • [Cites] J Assoc Physicians India. 2002 Nov;50:1435-7 [12583479.001]
  • [Cites] Ann Hematol. 2003 Apr;82(4):231-5 [12707726.001]
  • [Cites] Am J Hematol. 2007 May;82(5):405-8 [17133422.001]
  • [Cites] Bildgebung. 1994 Mar;61(1):37-9 [8193516.001]
  • [Cites] Ann Hematol. 1996 Dec;73(6):297-302 [9003161.001]
  • [Cites] Haematologica. 1998 Aug;83(8):760-1 [9793269.001]
  • [Cites] Jpn J Med. 1987 May;26(2):234-6 [3476781.001]
  • (PMID = 20046528.001).
  • [ISSN] 1976-2437
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2799964
  • [Keywords] NOTNLM ; Acute myeloid leukemia M2 / pathologic / splenic rupture
  •  go-up   go-down


53. Chen K, Wallis JW, McLellan MD, Larson DE, Kalicki JM, Pohl CS, McGrath SD, Wendl MC, Zhang Q, Locke DP, Shi X, Fulton RS, Ley TJ, Wilson RK, Ding L, Mardis ER: BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat Methods; 2009 Sep;6(9):677-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Detection and characterization of genomic structural variation are important for understanding the landscape of genetic variation in human populations and in complex diseases such as cancer.
  • We examined BreakDancer's performance in simulation, in comparison with other methods and in analyses of a sample from an individual with acute myeloid leukemia and of samples from the 1,000 Genomes trio individuals.

  • COS Scholar Universe. author profiles.
  • SciCrunch. SciCrunch Registry: Resource: Registry .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Res. 2008 Nov;18(11):1851-8 [18714091.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Nature. 2008 Nov 6;456(7218):60-5 [18987735.001]
  • [Cites] Nat Methods. 2009 Jan;6(1):99-103 [19043412.001]
  • [Cites] Nat Methods. 2009 Jul;6(7):473-4 [19483690.001]
  • [Cites] Genome Res. 2009 Jul;19(7):1270-8 [19447966.001]
  • [Cites] N Engl J Med. 2009 Sep 10;361(11):1058-66 [19657110.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7696-701 [12788976.001]
  • [Cites] Bioinformatics. 2003 Oct;19 Suppl 2:ii162-71 [14534186.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1916-21 [14769938.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]
  • [Cites] Nat Genet. 2005 Jul;37(7):727-32 [15895083.001]
  • [Cites] Nat Rev Genet. 2006 Feb;7(2):85-97 [16418744.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4534-9 [16537408.001]
  • [Cites] Nature. 2006 Nov 23;444(7118):444-54 [17122850.001]
  • [Cites] Nat Genet. 2006 Dec;38(12):1413-8 [17115057.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):233-45 [17361217.001]
  • [Cites] Science. 2007 Oct 19;318(5849):420-6 [17901297.001]
  • [Cites] PLoS Biol. 2007 Sep 4;5(10):e254 [17803354.001]
  • [Cites] Am J Hum Genet. 2008 Jan;82(1):214-21 [18179902.001]
  • [Cites] Science. 2008 Jan 25;319(5862):395 [18218868.001]
  • [Cites] Nat Genet. 2008 Mar;40(3):322-8 [18278044.001]
  • [Cites] Trends Genet. 2008 Mar;24(3):133-41 [18262675.001]
  • [Cites] Nature. 2008 Apr 17;452(7189):872-6 [18421352.001]
  • [Cites] Genome Res. 2008 May;18(5):821-9 [18349386.001]
  • [Cites] Nature. 2008 May 1;453(7191):56-64 [18451855.001]
  • [Cites] Nat Genet. 2008 Oct;40(10):1166-74 [18776908.001]
  • [Cites] Nature. 2008 Nov 6;456(7218):53-9 [18987734.001]
  • (PMID = 19668202.001).
  • [ISSN] 1548-7105
  • [Journal-full-title] Nature methods
  • [ISO-abbreviation] Nat. Methods
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA101937; United States / NHGRI NIH HHS / HG / U54 HG003079; United States / NHGRI NIH HHS / HG / HG003079
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA
  • [Other-IDs] NLM/ NIHMS133051; NLM/ PMC3661775
  •  go-up   go-down


54. Chen XH, Tong Y, Xu WL, Jin J, Qian WB: [Expression of telomere binding factor 2 (TRF2) on leukemia cell lines and primary leukemia cells]. Zhejiang Da Xue Xue Bao Yi Xue Ban; 2008 Mar;37(2):170-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of telomere binding factor 2 (TRF2) on leukemia cell lines and primary leukemia cells].
  • OBJECTIVE: To detect the expression levels of telomere binding factor 2 (TRF2) on leukemia cell lines and primary leukemia cells.
  • METHODS: The expression of TRF2 mRNA was detected with quantitative real-time RT-PCR in leukemia cell lines and primary leukemia cells.
  • RESULT: TRF2 was overexpressed in T-cell leukemia cell lines but not in myelogenous leukemia cell lines.
  • Significant higher expression levels of TRF2 were observed in primary leukemia cells from patients with M0 and M1 subtypes of acute myelogenous leukemia (AML) compared with normal control and other subtypes of AML.
  • CONCLUSION: Increased TRF2 expression levels are found in T-cell leukemia cell lines and AML patients with poor prognosis, which suggests that TRF2 expression might be related to the prognosis of leukemia.
  • [MeSH-major] Leukemia, T-Cell / metabolism. Telomeric Repeat Binding Protein 2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Female. HL-60 Cells. Humans. Jurkat Cells. K562 Cells. Leukemia, Myeloid, Acute / metabolism. Male. Middle Aged. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18422278.001).
  • [ISSN] 1008-9292
  • [Journal-full-title] Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  • [ISO-abbreviation] Zhejiang Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / TERF2 protein, human; 0 / Telomeric Repeat Binding Protein 2
  •  go-up   go-down


55. Ravnsborg T, Houen G, Højrup P: The glycosylation of myeloperoxidase. Biochim Biophys Acta; 2010 Oct;1804(10):2046-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of MPO can be used to distinguish acute myelogenous leukemia from acute lymphocytic leukemia.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20621206.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Polysaccharides; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


56. Karagiulian SR, Kovaleva LG, Danishian KI, Grzhimolovskiĭ AV, Sorokina OM, Bulanov AIu, Kolosova LIu: [One-stage spleen- and gastrectomy in a female patient with subleukemic myelosis with massive splenomegaly and gastric cancer]. Ter Arkh; 2008;80(7):72-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [One-stage spleen- and gastrectomy in a female patient with subleukemic myelosis with massive splenomegaly and gastric cancer].
  • [MeSH-major] Gastrectomy / methods. Leukemia, Myeloid / surgery. Neoplasms, Multiple Primary / surgery. Splenectomy / methods. Splenomegaly / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Splenomegaly.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18763604.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


57. Schmitt-Graeff AH: [Chronic myeloid neoplasms. Diagnostic criteria and current therapeutic concepts]. Pathologe; 2010 Feb;31(1):29-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chronic myeloid neoplasms. Diagnostic criteria and current therapeutic concepts].
  • [Transliterated title] Chronische myeloische Neoplasien. Diagnostische Kriterien und Ausblick auf aktuelle Theapiekonzepte.
  • Myeloproliferative neoplasms (MPNs) and related chronic disorders constitute a subgroup of myeloid malignancies which are defined according to clinical, morphological and molecular features by the actual World Health Organization classification of tumors of the haematopietic system.
  • Screening procedures for a BCR-ABL fusion gene, JAK2, thrombopoietin receptor and KIT mutations are formally included in the diagnostic approach.
  • The paradigm of targeted treatment of chronic myeloid leukemia with imatinib has now been extended to eosinophilia-associated myeloid neoplasms with PDGFRA, PDGFRB or FGFR1 gene mutations.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • [MeSH-minor] Alleles. Biomarkers, Tumor / genetics. Bone Marrow / pathology. DNA Mutational Analysis. Diagnosis, Differential. Humans. Leukemia, Myelomonocytic, Chronic / drug therapy. Leukemia, Myelomonocytic, Chronic / genetics. Leukemia, Myelomonocytic, Chronic / pathology. Molecular Diagnostic Techniques. Myeloproliferative Disorders / drug therapy. Myeloproliferative Disorders / genetics. Myeloproliferative Disorders / pathology. Polycythemia Vera / drug therapy. Polycythemia Vera / genetics. Polycythemia Vera / pathology. Primary Myelofibrosis / drug therapy. Primary Myelofibrosis / genetics. Primary Myelofibrosis / pathology. Prognosis. Protein-Tyrosine Kinases / antagonists & inhibitors. Signal Transduction / drug effects. Signal Transduction / genetics


58. Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD: Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol; 2008 Nov 1;26(31):5078-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
  • PURPOSE: To evaluate the prognostic significance of CEBPA mutations in the context of established molecular markers in cytogenetically normal (CN) acute myeloid leukemia (AML) and gain biologic insights into leukemogenesis of the CN-AML molecular high-risk subset (FLT3 internal tandem duplication [ITD] positive and/or NPM1 wild type) that has a significantly higher incidence of CEBPA mutations than the molecular low-risk subset (FLT3-ITD negative and NPM1 mutated).
  • RESULTS: CEBPA mutations predicted better event-free (P = .007), disease-free (P = .014), and overall survival (P < .001) independently of other molecular and clinical prognosticators.
  • Within this group, CEBPA mutations predicted better event-free (P < .001), disease-free (P = .004), and overall survival (P = .009) independently of other molecular and clinical characteristics and were associated with unique gene and miRNA expression profiles.
  • CONCLUSION: Pretreatment testing for CEBPA mutations identifies CN-AML patients with different outcomes, particularly in the molecular high-risk group, thus improving molecular risk-based classification of this large cytogenetic subset of AML.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Feb 15;99(4):1332-40 [11830484.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7233-9 [11585760.001]
  • [Cites] EMBO J. 2002 Jul 15;21(14):3770-81 [12110589.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2717-23 [12351377.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4372-80 [12393388.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):89-101 [12563308.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2206-14 [12406909.001]
  • [Cites] Hematol J. 2003;4(1):31-40 [12692518.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1613-8 [12750167.001]
  • [Cites] Immunity. 2003 Sep;19(3):451-62 [14499119.001]
  • [Cites] Science. 2004 Jan 2;303(5654):83-6 [14657504.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):624-33 [14726504.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):394-400 [15122210.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4290-301 [15514371.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1418-25 [8640834.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8705-10 [10411939.001]
  • [Cites] N Engl J Med. 2005 Jan 20;352(3):254-66 [15659725.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1372-9 [15746035.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1416-24 [15746041.001]
  • [Cites] Blood. 2005 Jul 15;106(2):673-80 [15797998.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5705-17 [16110030.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3618-20 [16046528.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3740-6 [16051734.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3733-9 [16076867.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9234-42 [16275934.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):790-7 [16418499.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6338-43 [16606850.001]
  • [Cites] Blood. 2006 May 15;107(10):4011-20 [16455956.001]
  • [Cites] Curr Opin Hematol. 2006 Jul;13(4):203-8 [16755214.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1677-83 [16670265.001]
  • [Cites] Blood. 2007 Jan 1;109(1):389-90 [17190859.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Exp Hematol. 2007 Apr;35(4):551-64 [17379065.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5164-7 [17341662.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2493-4; author reply 2494-5 [17557966.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3337-43 [17577018.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6766-76 [17934484.001]
  • [Cites] Nucleic Acids Symp Ser (Oxf). 2007;(51):415-6 [18029763.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):51-60 [17994017.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1552-9 [17940205.001]
  • [Cites] Leukemia. 2008 Mar;22(3):655-7 [17851556.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1919-28 [18450603.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5371-9 [18378853.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] Nat Genet. 2001 Mar;27(3):263-70 [11242107.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2434-9 [11290608.001]
  • [CommentIn] J Clin Oncol. 2009 Apr 20;27(12):2105; author reply 2106 [19273693.001]
  • [ErratumIn] J Clin Oncol. 2008 Dec 20;26(36):6021
  • (PMID = 18809607.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA16058; United States / NCI NIH HHS / CA / CA101140; United States / NCI NIH HHS / CA / CA09512; United States / NCI NIH HHS / CA / CA089341; United States / NCI NIH HHS / CA / CA96887; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA98933; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA90469
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAALC protein, human; 0 / Biomarkers, Tumor; 0 / CCAAT-Enhancer-Binding Proteins; 0 / CEBPA protein, human; 0 / ERG protein, human; 0 / MLL protein, human; 0 / MicroRNAs; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Trans-Activators; 0 / WT1 Proteins; 117896-08-9 / nucleophosmin; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Other-IDs] NLM/ PMC2652095
  •  go-up   go-down


59. Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G, Cortes J: Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood; 2008 Jul 1;112(1):53-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
  • Chronic myeloid leukemia (CML) with T315I mutation has been reported to have poor prognosis.
  • Although the T315I mutation is resistant to currently available TKIs, survival of patients with T315I remains mostly dependent on the stage of the disease, with many CP patients having an indolent course.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Piperazines / therapeutic use. Point Mutation. Protein Kinase Inhibitors / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Protein-Tyrosine Kinases / genetics. Pyrimidines / therapeutic use

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2002 Feb 9;359(9305):487-91 [11853795.001]
  • [Cites] Blood. 2007 Dec 1;110(12):4005-11 [17785585.001]
  • [Cites] J Biol Chem. 2002 Aug 30;277(35):32214-9 [12077114.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):117-25 [12204532.001]
  • [Cites] Curr Opin Hematol. 2004 Jan;11(1):35-43 [14676625.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3425-32 [15867244.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4500-5 [15930265.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2531-41 [16775234.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2542-51 [16775235.001]
  • [Cites] Blood. 2006 Sep 15;108(6):1809-20 [16709930.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1767-73 [16855631.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7374-9 [17189410.001]
  • [Cites] Blood. 2007 Jan 15;109(2):500-2 [16990603.001]
  • [Cites] Haematologica. 2007 Sep;92(9):1238-41 [17768119.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2204-6 [17541396.001]
  • [Cites] N Engl J Med. 2002 Feb 28;346(9):645-52 [11870241.001]
  • (PMID = 18403620.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Other-IDs] NLM/ PMC4081375
  •  go-up   go-down


60. Weinel S, Malone J, Jain D, Callen JP: Therapy-related leukaemia cutis: a review. Australas J Dermatol; 2008 Nov;49(4):187-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related leukaemia cutis: a review.
  • Leukaemia cutis following chemotherapy for a malignancy is a multifactorial process that is dependent on the chemotherapeutic agent used, the dosing regimen, and the cumulative dose as well as potential contributing therapies such as radiation and possibly even hematopoietic support from granulocyte colony stimulating factor.
  • In the right combination and in a patient with a conducive milieu of epigenetic factors, leukaemia can develop as a treatment complication.
  • Leukaemia cutis is the specific infiltration of the skin by leukaemic cells and occurs most commonly when the underlying leukaemia is an acute myeloid leukaemia.
  • Although it is well reviewed in the literature as a result of primary leukaemia, leukaemia cutis has only very rarely been reported in association with therapy-induced leukaemia.
  • This article reviews the factors that contribute to therapy-related leukaemia and the development of leukaemia cutis.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Myeloid, Acute / pathology. Leukemic Infiltration / etiology. Radiotherapy, Adjuvant / adverse effects. Skin / pathology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18855778.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Taxoids; 0 / Topoisomerase I Inhibitors; 0 / Topoisomerase II Inhibitors
  • [Number-of-references] 23
  •  go-up   go-down


61. Rémi J, Pfefferkorn T, König FB, Lassmann H, Brück W, Holtmannspötter M, Straube A, Kretzschmar HA, Schüller U: A 76-year-old woman with paraplegia. Brain Pathol; 2010 Mar;20(2):507-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Autopsy examination revealed an acute myeloid leukemia, which had not previously been diagnosed and which had never been treated.
  • This case implies that association of acute myeloid leukemia and acute CNS demyelination needs to be discussed and suggests that AML patients need to be strictly monitored for CNS functions.
  • [MeSH-major] Brain / pathology. Demyelinating Diseases / pathology. Leukemia, Myeloid, Acute / pathology. Paraplegia / pathology
  • [MeSH-minor] Acute Disease. Aged. Diagnosis, Differential. Fatal Outcome. Female. Humans

  • Genetic Alliance. consumer health - Paraplegia.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20438471.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


62. Stevenson GT: CD38 as a therapeutic target. Mol Med; 2006 Nov-Dec;12(11-12):345-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CD38 molecule is well represented on cell surfaces in many cases of a variety of lymphoid tumors, notably multiple myeloma, AIDS-associated lymphomas, and post-transplant lymphoproliferations.
  • First, a human IgG monoclonal anti-CD38 antibody raised in mice transgenic for human Ig has been found to induce potent complement and cellular cytotoxicities against both myeloma cell lines and fresh harvests from myeloma marrow and leukemic blood.
  • The list of candidate CD38-bearing neoplasms as targets for these antibody constructs can now be expanded to include acute promyelocytic leukemia, and possibly other myeloid leukemias, in which surface CD38 can be induced by retinoid treatment.
  • [MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Cell Line, Tumor. Humans. Leukemia / immunology. Lymphoma, B-Cell / immunology. Mice. Mice, SCID. Multiple Myeloma / immunology. Transplantation, Heterologous

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 2001 Jan;25(1):1-12 [11137554.001]
  • [Cites] Mol Cancer Ther. 2004 Mar;3(3):345-52 [15026555.001]
  • [Cites] Scand J Immunol. 1978 Apr;7(4):297-306 [418499.001]
  • [Cites] Am J Hematol. 1990 Feb;33(2):101-9 [2301368.001]
  • [Cites] Blood. 1991 Mar 1;77(5):1071-9 [1995092.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):352-6 [8380497.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1442-9 [7520771.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3017-25 [7524764.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1762-9 [15905193.001]
  • [Cites] Leuk Res. 2007 Apr;31(4):455-63 [16920192.001]
  • (PMID = 17380203.001).
  • [ISSN] 1076-1551
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; EC 3.2.2.5 / Antigens, CD38
  • [Other-IDs] NLM/ PMC1829201
  •  go-up   go-down


63. Singh H, Prasad BN, Jagdish, Batra A: Hyperleukocytosis associated pulmonary leukostasis in acute leukaemia. J Assoc Physicians India; 2006 May;54:405-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperleukocytosis associated pulmonary leukostasis in acute leukaemia.
  • Leukostasis is a fatal complication in granulocytic leukaemia.
  • In the lung, the clinical presentation simulates infections and haemorrhagic complications of acute leukaemia.
  • [MeSH-major] Leukemia / complications. Leukocytosis / etiology. Leukostasis / etiology. Lung Diseases / etiology

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16909741.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


64. Khare RK, Settimi PD, Mba NI, Wechsler DS, Bratton SL, Williams DM: Aortobronchial fistula in a pediatric patient with massive hemoptysis: treatment by means of an aortic endograft. Ann Thorac Surg; 2005 Aug;80(2):731-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present an 11-year-old girl with acute myelogenous leukemia and hemoptysis from abscess erosion into the descending thoracic aorta.
  • [MeSH-major] Aortic Diseases / surgery. Aspergillosis / complications. Blood Vessel Prosthesis Implantation / methods. Bronchial Fistula / surgery. Lung Diseases, Fungal / complications. Vascular Fistula / surgery
  • [MeSH-minor] Antifungal Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Aortography. Child. Embolization, Therapeutic. Female. Hemoptysis / etiology. Humans. Leukemia, Myeloid, Acute / drug therapy. Lung Abscess / complications. Lung Abscess / microbiology. Lung Abscess / therapy. Pneumonectomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16039247.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


65. Mizushima Y, Taki T, Shimada A, Yui Y, Hiraumi Y, Matsubara H, Watanabe M, Watanabe K, Kamitsuji Y, Hayashi Y, Tsukimoto I, Kobayashi R, Horibe K, Tawa A, Nakahata T, Adachi S: Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group. Int J Hematol; 2010 Jun;91(5):831-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group.
  • High BAALC (brain and acute leukemia, cytoplasmic) gene expression may indicate an adverse prognosis for adults who have acute myeloid leukemia (AML) and a normal karyotype, but its prognostic significance for pediatric AML cases is unclear.
  • [MeSH-major] Asian Continental Ancestry Group / genetics. CCAAT-Enhancer-Binding Proteins. Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / diagnosis. Mutation. Neoplasm Proteins


66. Borthakur G, Kantarjian H, Daley G, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Faderl S, Sugrue M, Cortes J: Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer; 2006 Jan 15;106(2):346-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
  • BACKGROUND: Lonafarnib (SCH66336) is a nonpeptidomimetic farnesyl transferase inhibitor that has demonstrated significant preclinical activity against chronic myelogenous leukemia (CML) cells and in CML animal models.
  • The median age of the patients was 62 years (range, 38-80 yrs) and the median time from the diagnosis of CML to therapy with lonafarnib was 5 years (range, 0.3-13 yrs).
  • Another patient with chronic phase disease had lowering of the leukocyte count without the need for hydroxyurea and normalization of the differential count that lasted for 5 months.
  • [MeSH-major] Farnesyltranstransferase / antagonists & inhibitors. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperidines / therapeutic use. Pyridines / therapeutic use

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16342165.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Piperidines; 0 / Pyridines; 0 / Pyrimidines; 193275-84-2 / lonafarnib; 8A1O1M485B / Imatinib Mesylate; EC 2.5.1.29 / Farnesyltranstransferase
  •  go-up   go-down


67. Joseph DE, Durosinmi MA: Neurological complications of chronic myeloid leukaemia: any cure? Niger J Clin Pract; 2008 Sep;11(3):246-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurological complications of chronic myeloid leukaemia: any cure?
  • OBJECTIVE: To attempt to explain the non-reversal, contrary to the widely held view, of the neurological deficits complicating chronic myeloid leukaemia.
  • METHOD: Using patients' case folders and haematological malignancy register all cases of chronic myeloid leukaemia seen in Jos University Teaching Hospital between July 1995 and June 2005 were retrospectively studied.
  • RESULTS: Thirty-three cases of chronic myeloid leukaemia were seen within the study period.
  • CONCLUSION: While the complications due to hyperleucocytosis-induced stasis recover following the conventional treatment, those due to other pathogenetic mechanisms such as leukaemic deposits do not return to their pre-morbid states following disease control despite the use of the currently available treatment protocols.
  • For future research, more still needs to be done to elicit other uncommon pathogenetic mechanisms underlying these complications with a view to finding specific treatment measures for worrisome chronic myeloid leukaemia-related sensori-neural deficits.
  • [MeSH-major] Brain Diseases / etiology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Nervous System Diseases / epidemiology. Nervous System Diseases / etiology. Nigeria / epidemiology. Prevalence. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Niger J Clin Pract. 2009 Mar;12(1):112. Emmanuel, J D [corrected to Joseph, D E]; Dorusinmi, M A [corrected to Durosinmi, M A]
  • (PMID = 19140362.001).
  • [ISSN] 1119-3077
  • [Journal-full-title] Nigerian journal of clinical practice
  • [ISO-abbreviation] Niger J Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


68. D'Orazio JA, Pulliam JF, Moscow JA: Spontaneous resolution of a single lesion of myeloid leukemia cutis in an infant: case report and discussion. Pediatr Hematol Oncol; 2008 Jun;25(5):457-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous resolution of a single lesion of myeloid leukemia cutis in an infant: case report and discussion.
  • Though infantile leukemia has a historically poor prognosis, there may be a subset of patients with cutaneous disease whose disease will resolve without therapy.
  • The authors report a case of infantile leukemia cutis who presented with a single subcutaneous chloroma that spontaneously resolved over the course of several weeks and who remains without evidence of disease nearly two years later.
  • After reviewing the literature of congenital leukemia cutis, the authors conclude that withholding chemotherapy in infants with cutaneous myeloid leukemia in the absence of known negative prognostic factors (MLL or BCR-ABL translocations) or progressive disease is clinically indicated.
  • [MeSH-major] Leukemia, Myeloid. Skin Neoplasms
  • [MeSH-minor] Humans. Infant. Remission, Spontaneous. Sarcoma, Myeloid

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18569848.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


69. Olivares R, Alfaro J, Díaz MC, Thompson L: [Disseminated fusariosis by Fusarium oxysporum in an adult patient with acute myeloid leukemia and severe febrile neutropenia]. Rev Chilena Infectol; 2005 Dec;22(4):356-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Disseminated fusariosis by Fusarium oxysporum in an adult patient with acute myeloid leukemia and severe febrile neutropenia].
  • [Transliterated title] Fusariosis diseminada por Fusarium oxysporum en un paciente adulto con leucemia mieloide aguda y neutropenia severa febril.
  • [MeSH-major] Fusarium. Immunocompromised Host. Leukemia, Myeloid, Acute / complications. Lung Diseases, Fungal / complications. Neutropenia / complications

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rev Chilena Infectol. 2006 Mar;23(1):87
  • (PMID = 16341358.001).
  • [ISSN] 0716-1018
  • [Journal-full-title] Revista chilena de infectología : órgano oficial de la Sociedad Chilena de Infectología
  • [ISO-abbreviation] Rev Chilena Infectol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


70. Lam TV, Agovino P, Niu X, Roché L: Linkage study of cancer risk among lead-exposed workers in New Jersey. Sci Total Environ; 2007 Jan 1;372(2-3):455-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancers of the stomach, breast, larynx, intrahepatic bile duct, and chronic myeloid leukemia were non-significantly elevated.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Data Collection / methods. Humans. Industry. Middle Aged. New Jersey / epidemiology. Occupational Diseases / chemically induced. Occupational Diseases / epidemiology. Risk Assessment. SEER Program

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. Lead, elemental .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17129599.001).
  • [ISSN] 0048-9697
  • [Journal-full-title] The Science of the total environment
  • [ISO-abbreviation] Sci. Total Environ.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-45025-40; United States / PHS HHS / / U55/CCU221914
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 2P299V784P / Lead
  •  go-up   go-down


71. Li WX, Cui CB, Cai B, Wang HY, Yao XS: Flavonoids from Vitex trifolia L. inhibit cell cycle progression at G2/M phase and induce apoptosis in mammalian cancer cells. J Asian Nat Prod Res; 2005 Aug;7(4):615-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast to the cell cycle G2/M phase inhibitory main effect on tsFT210 cells, 5 induced mainly apoptosis on human myeloid leukemia K562 cells with a weak inhibition of the cell cycle at the G2/M phase.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16087636.001).
  • [ISSN] 1028-6020
  • [Journal-full-title] Journal of Asian natural products research
  • [ISO-abbreviation] J Asian Nat Prod Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Flavonoids
  •  go-up   go-down


72. Song AX, Yang DL, Wei JL, Yan ZS, Wang M, Jiang EL, Huang Y, Liu QG, Ma QL, Zhai WH, Zhang RL, Feng SZ, Han MZ: [Allogeneic stem cell transplantation for 75 cases of acute myeloid leukemia in complete remission: outcome and prognostic analysis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb;18(1):161-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Allogeneic stem cell transplantation for 75 cases of acute myeloid leukemia in complete remission: outcome and prognostic analysis].
  • This study was purposed to evaluate the outcome of patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) in complete remission, and to study the prognostic factors.
  • Major end points of study included overall survival (OS), disease free survival (DFS), relapse rate and transplantation related mortality (TRM).
  • Different prognosis was observed between HSCT recipients of alternative donor and HLA-matched related donor (MRD) (3-year DFS was 34.3% vs 60.0%, p = 0.019), between patients of refractory leukemia and the control (3-year DFS was 35.7% vs 58.2%, p = 0.048), between recipients with and without severe aGVHD (3-year DFS was 35.7% vs 54.4%, p = 0.059).
  • Multivariate analysis revealed three negative prognostic factors: donor availability (alternative vs MRD) (p = 0.049, RR = 2.09, 95%CI 1.01 - 4.36), refractory leukemia (p = 0.038, RR = 2.33, 95%CI 1.05 - 5.20) and severe aGVHD (p = 0.040, RR = 2.33, 95%CI 1.04 - 5.20).
  • Donor availability, refractory leukemia and severe aGVHD are confirmed as risk factors of poor prognosis for allo-HSCT patients with AML in CR.


73. Hambley TW, Hait WN: Is anticancer drug development heading in the right direction? Cancer Res; 2009 Feb 15;69(4):1259-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The success of molecularly targeted agents, such as imatinib, has led to expectations of a new era in anticancer drug development, and to a greatly increased focus on targeting as a strategy.
  • However, the number of successes to date is small, and recent results suggest that the success of imatinib, for instance, in treating chronic myelogenous leukemia and gastrointestinal stromal tumor may be the exception rather than the rule.
  • [MeSH-minor] Benzamides. Drug Delivery Systems / methods. Drug Delivery Systems / trends. Gastrointestinal Stromal Tumors / drug therapy. Humans. Imatinib Mesylate. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19208831.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


74. Servida F, Soligo D, Delia D, Henderson C, Brancolini C, Lombardi L, Deliliers GL: Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. Leukemia; 2005 Dec;19(12):2324-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I.
  • The proteasome inhibitor PSI is potently cytotoxic in vitro against human chronic myeloid leukemia (CML) and acute myeloid leukemias (AML).
  • PSI potentiated the toxicity of a number of chemotherapeutic agents in myeloid leukemia but not in MM cell lines, while in combination with therapeutic proteasome inhibitor PS-341 (Bortezomib) it had a synergistic effect.
  • [MeSH-major] Cysteine Proteinase Inhibitors / pharmacology. Leukemia, Myeloid / drug therapy. Multiple Myeloma / drug therapy. Oligopeptides / pharmacology

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16224484.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cysteine Proteinase Inhibitors; 0 / Oligopeptides; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal; EC 3.4.22.- / Caspases
  •  go-up   go-down


75. Rytting ME, Kantarjian H, Albitar M: Acute lymphoblastic leukemia with Burkitt-like morphologic features and high myeloperoxidase activity. Am J Clin Pathol; 2009 Aug;132(2):182-5; quiz 306
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia with Burkitt-like morphologic features and high myeloperoxidase activity.
  • Expression of a high level of myeloperoxidase (MPO) as a sole myeloid marker in acute leukemias that express typical lymphoblastic markers is unusual.
  • Herein we report 5 cases of MPO+, otherwise typical acute lymphoblastic leukemia (ALL) without the expression of other myeloid markers.
  • The striking feature of most of these cases is a morphologic picture reminiscent of that seen in Burkitt-like B-cell ALL with basophilic cytoplasm and vacuoles but no expression of surface immunoglobulin.
  • All cases responded to ALL therapy and should be distinguished from myeloid leukemia and from Burkitt leukemia/lymphoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Peroxidase / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19605811.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


76. Miettinen M, Kraszewska E, Sobin LH, Lasota J: A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia. Cancer; 2008 Feb 1;112(3):645-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia.
  • These tumors most commonly occur in the stomach and small intestine and encompass a clinical spectrum from benign to malignant.
  • BACKGROUND: Nine patients (2 with gastric GISTs and 7 with GISTs of the small intestine) developed myeloid leukemia.
  • There were 6 patients (4 women and 2 men) with acute myeloid leukemia (AML), including 1 case of promyelocytic and 1 case of myelomonocytic leukemia, and 3 patients (2 men and 1 woman) with chronic myeloid leukemia (CML).
  • RESULTS: The leukemias developed 1.7 to 21 years after the GIST (median interval, 6 years).
  • None of the GIST patients had received radiotherapy or chemotherapy prior to the leukemia diagnosis.
  • Eight of 9 patients died of leukemia, and none died of GIST.
  • Standardized incidence ratios (SIRs) and their 95% confidence intervals (95% CIs) were calculated comparing the incidences of AML/CMLs in GIST patients with those in the 2000 through 2003 U.S. population.
  • CONCLUSIONS: Additional epidemiologic, clinical, and pathogenetic studies are needed to understand the apparent nonrandom association between GIST and myeloid leukemia.
  • [MeSH-major] Gastrointestinal Stromal Tumors / epidemiology. Intestinal Neoplasms / epidemiology. Leukemia, Myeloid / epidemiology. Stomach Neoplasms / epidemiology


77. Amitrano L, Guardascione MA, Schiavone EM, Brancaccio V, Antinolfi I, Iannaccone L, Ferrara F, Balzano A: Hepatic vein thrombosis leading to fulminant hepatic failure in a case of acute non-promyelocytic myelogenous leukemia. Blood Coagul Fibrinolysis; 2006 Jan;17(1):59-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic vein thrombosis leading to fulminant hepatic failure in a case of acute non-promyelocytic myelogenous leukemia.
  • Budd-Chiari syndrome is a rare disease due to occlusion of the hepatic veins often presenting with acute liver failure.
  • Common causes of Budd-Chiari syndrome are chronic myeloproliferative disorders, while acute leukemia has been associated with hepatic vein thrombosis in only two cases in the literature to date.
  • We report a case of Budd-Chiari syndrome complicating a non-promyelocytic acute myelogenous leukemia leading to fulminant hepatic failure.
  • [MeSH-major] Budd-Chiari Syndrome / etiology. Leukemia, Myeloid, Acute / complications. Liver Failure, Acute / etiology


78. Barnes K, McIntosh E, Whetton AD, Daley GQ, Bentley J, Baldwin SA: Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene; 2005 May 5;24(20):3257-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation.
  • In chronic myeloid leukaemia (CML) expression of the chimeric tyrosine kinase, Bcr-Abl, promotes the inappropriate survival of haemopoietic stem cells by a nonautocrine mechanism in the absence of IL-3.
  • [MeSH-major] Fusion Proteins, bcr-abl / metabolism. Glucose / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735728.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Benzamides; 0 / Cytokines; 0 / Enzyme Inhibitors; 0 / Glucose Transporter Type 1; 0 / Interleukin-3; 0 / Monosaccharide Transport Proteins; 0 / Piperazines; 0 / Proto-Oncogene Proteins; 0 / Pyrimidines; 0 / SLC2A1 protein, human; 8A1O1M485B / Imatinib Mesylate; 9G2MP84A8W / Deoxyglucose; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; IY9XDZ35W2 / Glucose; N12000U13O / Doxycycline
  •  go-up   go-down


79. Kern W, Haferlach T: [Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis]. Med Klin (Munich); 2005 Jan 15;100(1):54-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis].
  • In the setting of diagnosing acute myeloid leukemias (AML) this method is used not only to subclassify AML and separate it from acute lymphoblastic and biphenotypic leukemias but also for the identification of leukemia-associated aberrant immunophenotypes (LAIPs).
  • Since these LAIPs are defined individually for each patient, leukemic bone marrow cells can be detected during the course of treatment using the LAIP allowing the quantification of minimal residual disease (MRD) which is not detectable by cytomorphology.
  • Due to its close correlation with the course of the disease and with the risk of relapse the MRD represents an important prognostic parameter which is increasingly used for stratification of therapy in clinical trials.
  • [MeSH-major] Flow Cytometry / methods. Leukemia, Myeloid, Acute / diagnosis. Neoplasm, Residual / diagnosis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15654545.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Epitopes; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


80. Ryningen A, Stapnes C, Paulsen K, Lassalle P, Gjertsen BT, Bruserud O: In vivo biological effects of ATRA in the treatment of AML. Expert Opin Investig Drugs; 2008 Nov;17(11):1623-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: All-trans retinoic acid (ATRA) is mandatory in the treatment of acute promyelocytic leukaemia (APL).
  • Experimental studies suggest that ATRA can induce differentiation and apoptosis in leukaemia cells also for other acute myelogenous leukaemia (AML) subtypes, but the clinical observations are conflicting.
  • DESIGN AND METHODS: Twenty-two AML patients with non-APL disease received oral ATRA alone (22.5 mg/m2 twice daily) for two days, the patients thereafter continued ATRA together with valproic acid and theophylline.
  • Serum/plasma samples were collected before and after 2 days of ATRA, peripheral blood AML cells were collected from all 12 patients with circulating leukaemia cells (ClinicalTrials.gov NCT00175812; EudraCT no. 2004-001663-22).
  • Circulating leukaemia cells derived during therapy had increased intracellular levels of P21 (mean increase in mean fluorescence intensity (MFI) being 18.2%, p = 0.017), and decreased levels of Gata-2 (mean decrease in MFI 19%, p = 0.026), NF-kappaB p65 (mean decrease in MFI 15.4%, p = 0.033) and Bcl-2 (mean decrease in MFI 7.2%, p = 0.005).
  • CONCLUSIONS: In vivo ATRA treatment in AML affects leukaemic cell morphology, regulation of cell cycle progression and apoptosis, and possibly also microvascular endothelial cell functions.
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy. Tretinoin / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18922099.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00175812
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Histone Deacetylase Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Transcription Factors; 5688UTC01R / Tretinoin; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


81. Roskoski R Jr: Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor. Biochem Biophys Res Commun; 2005 Dec 23;338(3):1307-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gain-of-function mutations of Kit are associated with several human neoplasms including acute myelogenous leukemia, gastrointestinal stromal tumors, mastocytomas, and nasal T-cell lymphomas.
  • The juxtamembrane domain inhibits enzyme activity in cis by maintaining the control alphaC-helix and the activation loop in their inactive conformations.
  • STI-571 binds to Kit and Bcr-Abl (the oncoprotein of chronic myelogenous leukemia) at their ATP-binding sites.


82. Bosi A, Bartolozzi B, Guidi S: Allogeneic stem cell transplantation. Transplant Proc; 2005 Jul-Aug;37(6):2667-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The main reported indications were as follows: leukemia, lymphoproliferative diseases, myelodysplasia, and nonmalignant diseases such as thalassemia and severe aplastic anemia.
  • In contrast, the availability of the Tyrosine kinase inhibitor (STI-571) for treatment of patients affected by chronic myelogenous leukemia, which was formerly the main indication for HSCT, has produced a dramatic decrease in the number of transplantations in this setting.
  • HSCT performed in the early phases of disease and in young patients offers more than a 50% cure rate.
  • As regards relapses, they correlate with disease status at the time of transplantation.
  • [MeSH-minor] Hematologic Diseases / therapy. Humans. Italy. Leukemia / therapy. Retrospective Studies. Tissue Donors / statistics & numerical data. Transplantation, Autologous / statistics & numerical data. Transplantation, Homologous / statistics & numerical data

  • Genetic Alliance. consumer health - Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16182779.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


83. Gözdaşoğlu S, Ertem M, Uysal Z, Babacan E, Yüksel M, Bökesoy I, Sunguroğlu A, Arcasoy A, Çavdar A: Acute myeloid leukemia in Turkish children with Fanconi anemia. One center experience in the period between 1964-1995. Turk J Haematol; 2009 Sep 5;26(3):118-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia in Turkish children with Fanconi anemia. One center experience in the period between 1964-1995.
  • [Transliterated title] Fanconi anemili Türk çocuklarında akut miyeloid lösemi. 1964-1995 döneminde bir merkezin deneyimleri.
  • OBJECTIVE: Fanconi's anemia(FA) is an autosomal recessive disorder characterized by a progressive pancytopenia,variable congenital abnormalities and an increased risk for the development of acute myeloid leukemia (AML).
  • CONCLUSION: Acute myelomonocytic type in three cases and acute monocytic type in one patient were diagnosed in our series.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265494.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


84. van der Meer A, Schaap NP, Schattenberg AV, van Cranenbroek B, Tijssen HJ, Joosten I: KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients. Mol Immunol; 2008 Aug;45(13):3631-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients.
  • The effect of NK alloreactivity in HLA identical SCT is still under debate and in particular in transplantation for chronic myeloid leukemia (CML) the data are very limited and with conflicting outcome.
  • The aim of our study was to evaluate the effect of KIR genes and KIR ligands on leukemia free survival (LFS) and relapse rate in a well-defined, homogeneous group of CML patients phase upon HLA identical sibling SCT.
  • In the latter group, the stimulatory KIR2DS5 gene was associated with improved leukemia free survival (p=0.007; hazard ratio 4.3; 95% confidence interval 1.3-6.7) and lower relapse rates (p=0.028; HR 4.3, 95% CI 1.1-9.1).
  • [MeSH-major] Genetic Linkage. HLA Antigens / immunology. Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Receptors, KIR / genetics
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Gene Frequency. Humans. Male. Middle Aged. Retrospective Studies. Transplantation, Homologous / immunology


85. Park TH, Kwon HC, Kim HJ, Han JY, Jeong JS, Han HY, Seo C, Kwak JY, Park JI: Detection of single nucleotide insertion of BCR/ABL region in imatinib-resistant human myelogenous leukemia SR-1 cells. Exp Mol Med; 2005 Oct 31;37(5):507-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of single nucleotide insertion of BCR/ABL region in imatinib-resistant human myelogenous leukemia SR-1 cells.
  • Imatinib mesylate is a selective Bcr/Abl kinase inhibitor and an effective anticancer agent for Bcr/Abl-positive chronic myelogenous leukemia.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Fusion Proteins, bcr-abl / genetics. Leukemia, Myeloid / genetics. Mutagenesis, Insertional / genetics. Piperazines / pharmacology. Point Mutation / genetics. Pyrimidines / pharmacology

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16264277.001).
  • [ISSN] 1226-3613
  • [Journal-full-title] Experimental & molecular medicine
  • [ISO-abbreviation] Exp. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Benzamides; 0 / Nucleotides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


86. Carella AM, Lerma E: Imatinib mesylate in chronic myeloid leukemia. Curr Stem Cell Res Ther; 2007 Sep;2(3):249-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate in chronic myeloid leukemia.
  • Chronic myeloid leukemia has become a paradigm for the discovery of target therapeutic approaches in the field of onco-hematology.
  • Recognition of the tyrosine kinase activity of the p210Bcr-Abl oncoprotein led to the development of compounds targeting against BCR-ABL and then controlling the leukemic proliferation.
  • According to five-years experience with this drug, it is recommended that the golden standard for initial treatment of newly diagnosis chronic myeloid leukemia patients should be 400 mg Imatinib daily.
  • In this brief review, we discuss the current tools for the effective management of chronic myeloid leukemia with Imatinib, providing the updated results of IRIS and RIGHT clinical trials and then the suggestions how Imatinib-treated patients should be monitored.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Chronic-Phase / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use


87. Grabrucker C, Liepert A, Dreyig J, Kremser A, Kroell T, Freudenreich M, Schmid C, Schweiger C, Tischer J, Kolb HJ, Schmetzer H: The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells. J Immunother; 2010 Jun;33(5):523-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
  • Adoptive immunotherapy is an important therapy option to reduce relapse rates after stem-cell transplantation in patients suffering from acute myeloid leukemia and myelodysplastic syndromes.
  • Myeloid leukemic cells can regularly be induced to differentiate into leukemia-derived dendritic cells (DC(leu)), regaining the stimulatory capacity of professional dendritic cells (DCs) while presenting the known/unknown leukemic antigen repertoire.
  • To further elicit DC/DC(leu)-induced T-cell-response patterns, we generated DC from 17 Acute myeloid leukemia (AML) and 2 myelodysplastic syndrome cases and carried out flowcytometry and (functional) nonradioactive fluorolysis assays before/after mixed lymphocyte cultures of matched (allogeneic) donor T cells (n=6), T cells prepared at relapse after stem-cell transplantation (n=4) or (autologous) patients' T cells (n=7) with blast containing mononuclear cells ("MNC") or DC(leu) ("DC").
  • We could define DC subtypes and cut-off proportions of DC subtypes/qualities (mature DC/DC(leu)) after "DC" priming, which were predictive for an antileukemic activity of primed T cells and the clinical course of the disease after immunotherapy (allogeneic stem-cell transplantation/donor lymphocytes infusion/therapy).
  • In summary, our data show that the composition and quality of DC after a mixed lymphocyte culture-priming phase is predictive for a successful ex vivo antileukemic response, especially with respect to proportions of mature and leukemia-derived DC.
  • These data contribute not only to predict DC-mediated functions or the clinical course of the diseases but also to develop and refine DC-vaccination strategies that may pave the way to develop and modify adoptive immunotherapy, especially for patients at relapse after allogeneic stem-cell transplantation.
  • [MeSH-major] Dendritic Cells / metabolism. Immunotherapy, Adoptive. Leukemia, Myeloid, Acute / diagnosis. Myelodysplastic Syndromes / diagnosis. T-Lymphocytes / metabolism


88. Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J: Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol; 2008 Feb 1;26(4):577-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
  • This reduction makes it possible for patients who are ineligible for high-dose myeloablative conditioning allo-SCT to benefit from graft-versus-leukemia reaction.
  • In this multicenter, prospective study of patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), we investigated the efficacy of RIC allo-SCT from a human leukocyte antigen-identical sibling by using a regimen that uses fludarabine and busulfan.
  • Graft-versus-host disease (GVHD) prophylaxis consisted of cyslosporine and methotrexate or mycophenolate mofetil.
  • The 1- and 4-year relapse cumulative incidences were 23% and 37%, respectively, and leukemia recurrence was the main cause of death.
  • The 4-year disease-free survival (DFS) and overall survival (OS) rates were 43% and 45%, respectively.
  • CONCLUSION: Our results confirm the capacity of this RIC regimen to obtain long-term remissions in patients ineligible for a conventional allo-SCT.
  • [MeSH-major] Graft vs Host Disease / prevention & control. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / therapy. Transplantation Conditioning
  • [MeSH-minor] Adult. Aged. Busulfan / administration & dosage. Chronic Disease. Disease-Free Survival. Drug Therapy, Combination. Female. Humans. Immunosuppressive Agents / administration & dosage. Male. Middle Aged. Multivariate Analysis. Myeloablative Agonists / administration & dosage. Prospective Studies. Remission Induction. Survival Analysis. Transplantation, Homologous. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives


89. Gogtay J, Chahchad S, Jadhav S, Purandare S: Response to the case report by Mattar: Generic Imatinib (Imatib, Cipla) in a patient with chronic myeloid leukemia in chronic phase. Int J Hematol; 2010 Dec;92(5):772-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to the case report by Mattar: Generic Imatinib (Imatib, Cipla) in a patient with chronic myeloid leukemia in chronic phase.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myelomonocytic, Chronic / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Int J Hematol. 2010 Jan;91(1):104-6 [20054670.001]
  • [Cites] Int J Hematol. 2010 Jan;91(1):104-6 [20054670.001]
  • (PMID = 21082296.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Drugs, Generic; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


90. Hayashi T, Ishioka M, Ito N, Kato Y, Nakagawa H, Hatano H, Mizuki N: Bilateral herpes simplex keratitis in a patient with chronic graft-versus-host disease. Clin Ophthalmol; 2008 Jun;2(2):457-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral herpes simplex keratitis in a patient with chronic graft-versus-host disease.
  • PURPOSE: To describe a case of bilateral herpes simplex keratitis accompanying chronic graft-versus-host disease (GVHD).
  • CASE REPORT: An 11-year-old boy with myelocytic leukemia underwent allogeneic bone marrow transplantation.
  • CONCLUSIONS: Herpes keratitis should be considered in the differential diagnosis of bilateral keratitis in patients with reduced immunocompetence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ophthalmol. 1991 Oct 15;112(4):468-9 [1928259.001]
  • [Cites] Trans Ophthalmol Soc U K. 1975 Jul;95(2):267-76 [775699.001]
  • [Cites] Bone Marrow Transplant. 2004 May;33(10):1031-5 [15048138.001]
  • (PMID = 19668737.001).
  • [ISSN] 1177-5467
  • [Journal-full-title] Clinical ophthalmology (Auckland, N.Z.)
  • [ISO-abbreviation] Clin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2693989
  • [Keywords] NOTNLM ; bilateral herpes simplex keratitis / bone marrow transplant / chronic graft-versus-host disease / corneal herpes / dry eyes
  •  go-up   go-down


91. Brière J: [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome]. Bull Acad Natl Med; 2007 Mar;191(3):535-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
  • [Transliterated title] Thrombocytémie essentielle. Apport de la mutation V617F de JAK2 pour la stratégie diagnostique, la physiopathologie et les modalités évolutives.
  • Secondary thrombocytosis is a reactive process in relation with acute or chronic inflammatory diseases, or asplenia.
  • However, the most frequent causes of chronic thrombocytosis in adults are the so-called chronic myeloproliferative syndromes (chronic myelocytic leukaemia, polycythemia vera, primary myelofibrosis, essential thrombocytemia), and to a lesser extent, myelodysplastic syndromes.
  • In the course of these disorders, thrombocytosis is often the first recognized abnormality.
  • Chronic myelocytic leukaemia is easily diagnosed owing to the presence of either the Philadelphia chromosome or the BCR-ABL fusion gene product.
  • The next step still relies upon a distinction according to the PVSG or the WHO criteria of Polycythemia Vera (PV) and Idiopathic myelo fibrosis (IMF) to finally confirm genuine Essential Thrombocythemia (ET).
  • The exclusion of PV and of IMF, including pre fibrotic and early fibrotic forms is still required for the diagnosis of "true" ET.
  • Disease stratification and treatment strategy are targeted on the evaluation and prevention of vascular complications.
  • Acute leukaemia or myelodysplasia, and other clonal progressions like myelofibrotic transformation, are infrequent and delayed events.
  • [MeSH-minor] Adult. Biopsy. Bone Marrow / pathology. Cohort Studies. Diagnosis, Differential. Disease Progression. Female. Humans. Male. Middle Aged. Mutation. Myeloproliferative Disorders / diagnosis. Myeloproliferative Disorders / genetics. Philadelphia Chromosome. Polycythemia Vera / diagnosis. Polycythemia Vera / genetics. Primary Myelofibrosis / diagnosis. Primary Myelofibrosis / genetics. Prognosis. Risk Factors. World Health Organization

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18072652.001).
  • [ISSN] 0001-4079
  • [Journal-full-title] Bulletin de l'Académie nationale de médecine
  • [ISO-abbreviation] Bull. Acad. Natl. Med.
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 56
  •  go-up   go-down


92. Liu YC, Miyazawa K, Sashida G, Kodama A, Ohyashiki K: Deletion (20q) as the sole abnormality in Waldenström macroglobulinemia suggests distinct pathogenesis of 20q11 anomaly. Cancer Genet Cytogenet; 2006 Aug;169(1):69-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletion (20q) as the sole abnormality in Waldenström macroglobulinemia suggests distinct pathogenesis of 20q11 anomaly.
  • The deletion of the long arm of chromosome 20, or del(20q), is a common cytogenetic abnormality in various myeloid disorders but is less commonly seen in lymphoid neoplasms.
  • Reviewing all 11 reported cases of plasma cell dyscrasia possessing sole del(20q), including our case, none of 4 cases with del(20q) as an initial anomaly developed myelodysplastic syndrome-acute myeloid leukemia (MDS/AML), but at least 3 cases with del(20q) appearing after chemotherapy developed MDS/AML at or after the time of del(20q).
  • We propose that the del(20q) may have different clinical significance in plasma cell dyscrasia: one is when del(20q) appears at diagnosis and may involve the initial event of oncogenesis, and the other is when del(20q) appears after treatment and is associated with therapy-related and potential MDS/AML risk.


93. Haylock DN, Nilsson SK: Osteopontin: a bridge between bone and blood. Br J Haematol; 2006 Sep;134(5):467-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overexpression of Opn is a feature of haemopoietic malignancies, such as multiple myeloma and chronic myeloid leukaemia, although its exact role in the aetiology and progression of these diseases remains unclear.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16848793.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD29; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 106441-73-0 / Osteopontin
  • [Number-of-references] 96
  •  go-up   go-down


94. Suzuki T, Koyama Y, Ichikawa H, Tsushima K, Abe K, Hayakawa S, Kuruto-Niwa R, Nozawa R, Isemura M: 1,25-Dihydroxyvitamin D3 suppresses gene expression of eukaryotic translation initiation factor 2 in human promyelocytic leukemia HL-60 cells. Cell Struct Funct; 2005;30(1):1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 1,25-Dihydroxyvitamin D3 suppresses gene expression of eukaryotic translation initiation factor 2 in human promyelocytic leukemia HL-60 cells.
  • The physiologically active metabolite of vitamin D(3), 1alpha,25-dihydroxyvitamin D(3) (DVD), is a potent inducer of cell differentiation in human myeloid leukemia cells.
  • [MeSH-major] Calcitriol / pharmacology. Eukaryotic Initiation Factor-2 / genetics. Gene Expression Regulation, Leukemic / drug effects

  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951637.001).
  • [ISSN] 1347-3700
  • [Journal-full-title] Cell structure and function
  • [ISO-abbreviation] Cell Struct. Funct.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Eukaryotic Initiation Factor-2; 0 / Neoplasm Proteins; FXC9231JVH / Calcitriol
  •  go-up   go-down


95. Hui CK, Yu J, Au WY, Zhang HY, Bartholomeusz A, Locarnini S, Kwong YL, Liang R, Lau GK: Sexual transmission of hepatitis B infection despite the presence of hepatitis B virus immunity in recipients of allogeneic bone marrow transplantation. J Clin Virol; 2005 Feb;32(2):173-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Two male patients with acute myeloid leukemia and light chain myeloma, respectively, developed HBV-related hepatitis more than 2 years after HCT.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Hepatitis B / immunology. Hepatitis B / transmission. Hepatitis B Antibodies / blood. Sexually Transmitted Diseases, Viral / transmission. Transplantation, Homologous / adverse effects
  • [MeSH-minor] Adult. DNA, Viral / analysis. Female. Hepatitis B Surface Antigens / immunology. Hepatitis B virus / classification. Hepatitis B virus / genetics. Hepatitis B virus / immunology. Heterosexuality. Humans. Immunity. Male. Middle Aged. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15653422.001).
  • [ISSN] 1386-6532
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Hepatitis B Antibodies; 0 / Hepatitis B Surface Antigens
  •  go-up   go-down


96. Lichtman MA: Battling the hematological malignancies: the 200 years' war. Oncologist; 2008 Feb;13(2):126-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The delineation of the hematological malignancies began near the end of the first third of the 19th century with the recognition of the similarity among cases with lymph node tumors and an enlarged spleen (Hodgkin's disease).
  • Descriptions of chronic and acute leukemia and myeloma followed thereafter.
  • In the first years of the 20th century the discovery of x-radiation permitted palliative orthovoltage radiation therapy of Hodgkin's disease.
  • Despite remarkable progress, including the ability to cure acute leukemia in about 70% of children, cure several genetic variants of acute myelogenous leukemia in younger adults, cure some cases of lymphoma in children and younger adults, and induce prolonged remission in many affected persons, the majority of patients face an uncertain outcome and shortened life.
  • These challenges will be gradually overcome, if we (a) develop new models of cooperation among academia, industry, and government, (b) continue the growth of international participation in cancer research (more keen minds to the task), and (c) convince the governments of the world, including that of the U.S., that an investment in minimizing the effects of cancer is as important as defending against other threats to the welfare and longevity of their citizens.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia / drug therapy. Lymphoma / drug therapy. Multiple Myeloma / drug therapy
  • [MeSH-minor] Age Factors. Genetic Predisposition to Disease. History, 19th Century. History, 20th Century. History, 21st Century. Humans. Risk Factors. Time Factors. Treatment Outcome


97. Kuendgen A, Gattermann N: Valproic acid for the treatment of myeloid malignancies. Cancer; 2007 Sep 1;110(5):943-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Valproic acid for the treatment of myeloid malignancies.
  • Recently, it was demonstrated that VPA also acts as a histone deacetylase inhibitor and induces differentiation and apoptosis in a variety of malignant cells in vitro.
  • Clinical trials with VPA have focused on acute myeloid leukemia and the myelodysplastic syndromes.
  • [MeSH-major] Apoptosis / drug effects. Leukemia, Myeloid / drug therapy. Tretinoin / pharmacology. Valproic Acid / pharmacology
  • [MeSH-minor] Acute Disease. Cell Line, Tumor. Drug Synergism. Drug Therapy, Combination. Histone Deacetylase Inhibitors. Humans

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer. 2008 May 15;112(10):2324-5; author reply 2325 [18348302.001]
  • (PMID = 17647267.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histone Deacetylase Inhibitors; 5688UTC01R / Tretinoin; 614OI1Z5WI / Valproic Acid
  • [Number-of-references] 75
  •  go-up   go-down


98. Chang G, Meadows ME, Jones JA, Antin JH, Orav EJ: Substance use and survival after treatment for chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS). Am J Drug Alcohol Abuse; 2010 Jan;36(1):1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Substance use and survival after treatment for chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS).
  • METHOD: Prospective cohort study of 106 adults with chronic myelogenous leukemia or primary myelodysplastic syndrome.
  • CONCLUSION: The results of this study highlight the potential significance of substance use disorders, and lifetime cocaine diagnoses in particular, on treatment outcome for people with chronic myelogenous leukemia or myelodysplastic syndrome.


99. Löwenberg B: Acute myeloid leukemia: the challenge of capturing disease variety. Hematology Am Soc Hematol Educ Program; 2008;:1-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia: the challenge of capturing disease variety.
  • The difference between success and failure of treatment of acute myeloid leukemia (AML) is largely determined by genotypic leukemia-specific differences among patients.
  • The diversity of AML genotypes result from somatic genetic alterations settling down in succession in an individual's leukemia clone during the development of the disease.
  • Gene mutations, gene expression abnormalities and other molecular alterations (e.g., microRNA variations) affect critical functions in AML cells, and may exert profound effects on the therapeutic response and outcome of the disease.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074046.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Genetic Markers; 0 / MECOM protein, human; 0 / MicroRNAs; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Transcription Factors
  • [Number-of-references] 80
  •  go-up   go-down


100. Vermeersch P, Zachee P, Brusselmans C: Acute myeloid leukemia with bone marrow necrosis and Charcot Leyden crystals. Am J Hematol; 2007 Nov;82(11):1029
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia with bone marrow necrosis and Charcot Leyden crystals.
  • [MeSH-major] Glycoproteins / metabolism. Leukemia, Myeloid, Acute / complications. Lysophospholipase / metabolism. Osteonecrosis / etiology






Advertisement